U.S. patent application number 13/618922 was filed with the patent office on 2013-01-24 for exendin and exendin agonists for eating disorders.
This patent application is currently assigned to AMYLIN PHARMACEUTICALS, LLC.. The applicant listed for this patent is Sunil Bhavsar, Bronislava Gedulin, Andrew A. Young. Invention is credited to Sunil Bhavsar, Bronislava Gedulin, Andrew A. Young.
Application Number | 20130023470 13/618922 |
Document ID | / |
Family ID | 27488253 |
Filed Date | 2013-01-24 |
United States Patent
Application |
20130023470 |
Kind Code |
A1 |
Young; Andrew A. ; et
al. |
January 24, 2013 |
EXENDIN AND EXENDIN AGONISTS FOR EATING DISORDERS
Abstract
Methods for treating conditions or disorders which can be
alleviated by reducing food intake are disclosed which comprise
administration of an effective amount of an exendin or an exendin
agonist, alone or in conjunction with other compounds or
compositions that affect satiety. The methods are useful for
treating conditions or disorders, including obesity, Type II
diabetes, eating disorders, and insulin-resistance syndrome. The
methods are also useful for lowering the plasma glucose level,
lowering the plasma lipid level, reducing the cardiac risk,
reducing the appetite, and reducing the weight of subjects.
Pharmaceutical compositions for use in the methods of the invention
are also disclosed.
Inventors: |
Young; Andrew A.; (Research
Triangle Park, NC) ; Bhavsar; Sunil; (San Diego,
CA) ; Gedulin; Bronislava; (Del Mar, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Young; Andrew A.
Bhavsar; Sunil
Gedulin; Bronislava |
Research Triangle Park
San Diego
Del Mar |
NC
CA
CA |
US
US
US |
|
|
Assignee: |
AMYLIN PHARMACEUTICALS,
LLC.
San Diego
CA
|
Family ID: |
27488253 |
Appl. No.: |
13/618922 |
Filed: |
September 14, 2012 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12766195 |
Apr 23, 2010 |
8288338 |
|
|
13618922 |
|
|
|
|
10895909 |
Jul 20, 2004 |
7741269 |
|
|
12766195 |
|
|
|
|
09003869 |
Jan 7, 1998 |
6956026 |
|
|
10895909 |
|
|
|
|
08908867 |
Aug 8, 1997 |
6858576 |
|
|
10895909 |
|
|
|
|
08694954 |
Aug 8, 1996 |
|
|
|
08908867 |
|
|
|
|
60065442 |
Nov 14, 1997 |
|
|
|
60066029 |
Nov 14, 1997 |
|
|
|
60055404 |
Aug 8, 1997 |
|
|
|
60034905 |
Jan 7, 1997 |
|
|
|
Current U.S.
Class: |
514/5.8 ;
514/11.7 |
Current CPC
Class: |
Y10S 514/866 20130101;
A61K 38/23 20130101; A61K 9/0019 20130101; A61K 47/44 20130101;
A61K 47/02 20130101; A61K 38/22 20130101; A61P 3/00 20180101; A61P
3/04 20180101; A61K 47/10 20130101; A61P 9/00 20180101; A61P 3/06
20180101; A61K 38/00 20130101; A61P 3/10 20180101; A61K 38/2207
20130101; A61K 47/26 20130101; A61K 38/2264 20130101; A61K 47/12
20130101; C07K 14/57563 20130101; A61K 38/22 20130101; A61K 2300/00
20130101; A61K 38/2207 20130101; A61K 2300/00 20130101; A61K
38/2264 20130101; A61K 2300/00 20130101; A61K 38/23 20130101; A61K
2300/00 20130101 |
Class at
Publication: |
514/5.8 ;
514/11.7 |
International
Class: |
A61K 38/26 20060101
A61K038/26; A61P 3/00 20060101 A61P003/00; A61P 9/00 20060101
A61P009/00 |
Claims
1. A method for treating a condition associated with hypernutrition
or reducing the cardiac risk in a human in need thereof comprising
administering to the human a therapeutically effective amount of an
exendin peptide or an exendin agonist analog peptide to treat the
condition associated with hypernutrition or reduce the cardiac risk
in the human.
2. The method of claim 1 for treating the condition associated with
hypernutrition in the human in need thereof.
3. The method of claim 1 for reducing the cardiac risk in the human
in need thereof.
4. The method of claim 1, wherein the exendin peptide or the
exendin agonist analog peptide is exendin-4.
5. The method of claim 1, wherein the exendin peptide or the
exendin agonist analog peptide comprises an amino acid sequence of
any one of SEQ ID NOs:1-188.
6. The method of claim 1, further comprising administering a
therapeutically effective amount of an amylin, an amylin agonist, a
leptin, a calcitonin, a cholecystokinin, or a combination of two or
more thereof.
7. The method of claim 1, further comprising administering a
therapeutically effective amount of pramlintide.
8. A pharmaceutical formulation comprising exendin-4 and a citrate
buffer.
9. A pharmaceutical formulation comprising an exendin peptide or an
exendin agonist analog peptide, wherein the pharmaceutical
formulation has a pH from 3.0 to 7.0.
10. The pharmaceutical formulation of claim 9, wherein the exendin
peptide or the exendin agonist analog peptide is exendin-4 and the
pharmaceutical formulation has a pH from 4.0 to 6.0.
11. The pharmaceutical formulation of claim 9 having a pH from 4.0
to 5.0.
12. The pharmaceutical formulation of claim 9, wherein the exendin
peptide or the exendin agonist analog peptide comprises an amino
acid sequence of any one of SEQ ID NOs:1-188.
13. The pharmaceutical formulation of claim 9, further comprising a
buffer selected from the group consisting of an acetate buffer, a
phosphate buffer, a citrate buffer, and a glutamate buffer.
Description
RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser.
No. 12/766,195 filed Apr. 23, 2010, which is a continuation of U.S.
application Ser. No. 10/895,909 filed Jul. 20, 2004 (issued as U.S.
Pat. No. 7,741,269), which is a continuation of U.S. application
Ser. No. 09/003,869 filed Jan. 7, 1998 (issued as U.S. Pat. No.
6,956,026), which claims priority to U.S. Application No.
60/034,905 filed Jan. 7, 1997, U.S. Application No. 60/055,404
filed Aug. 8, 1997, U.S. Application No. 60/066,029 filed Nov. 14,
1997, and U.S. Application No. 60/065,442 filed Nov. 14, 1997, each
of which is incorporated herein by reference in its entirety for
all purposes. U.S. application Ser. No. 10/895,909 filed Jul. 20,
2004 (issued as U.S. Pat. No. 7,741,269), is also a
continuation-in-part of U.S. application Ser. No. 08/908,867 filed
Aug. 8, 1997 (issued as U.S. Pat. No. 6,858,576), which is a
continuation-in-part of U.S. application Ser. No. 08/694,954 filed
Aug. 8, 1996, abandoned, both of which are incorporated herein by
reference in their entirety for all purposes.
FIELD OF THE INVENTION
[0002] The present invention relates to methods for treating
conditions or disorders which can be alleviated by reducing food
intake comprising administration of an effective amount of an
exendin or an exendin agonist alone or in conjunction with other
compounds or compositions that affect satiety such as a leptin or
an amylin agonist. The methods are useful for treating conditions
or disorders, in which the reduction of food intake is of value,
including obesity, Type II diabetes, eating disorders, and
insulin-resistance syndrome. The methods are also useful for
lowering the plasma lipid level, reducing the cardiac risk,
reducing the appetite, and reducing the weight of subjects.
Pharmaceutical compositions for use in the methods of the invention
are also disclosed.
BACKGROUND
[0003] The following description summarizes information relevant to
the present invention. It is not an admission that any of the
information provided herein is prior art to the presently claimed
invention, nor that any of the publications specifically or
implicitly referenced are prior art to that invention.
[0004] Exendins are peptides that are found in the venom of the
Gila-monster, a lizard found in Arizona, and the Mexican Beaded
Lizard. Exendin-3 is present in the venom of Heloderma horridum,
and exendin-4 is present in the venom of Heloderma suspectum (Eng,
J., et al., J. Biol. Chem., 265:20259-62, 1990; Eng., J., et al.,
J. Biol. Chem., 267:7402-05, 1992). The exendins have some sequence
similarity to several members of the glucagon-like peptide family,
with the highest homology, 53%, being to GLP-1[7-36]NH.sub.2 (Goke,
et al., J. Biol. Chem., 268:19650-55, 1993). GLP-1[7-36]NH.sub.2,
also known as proglucagon[78-107], has an insulinotropic effect,
stimulating insulin secretion from pancreatic .beta.-cells; GLP
also inhibits glucagon secretion from pancreatic .alpha.-cells
(Orskov, et al., Diabetes, 42:658-61, 1993; D'Alessio, et al., J.
Clin. Invest., 97:133-38, 1996). GLP-1 is reported to inhibit
gastric emptying (Williams B, et al., J Clin Endocrinol Metab 81
(1): 327-32, 1996; Wettergren A, et al., Dig Dis Sci 38 (4):
665-73, 1993), and gastric acid secretion. (Schjoldager B T, et
al., Dig Dis Sci 34 (5): 703-8, 1989; O'Halloran D J, et al., J
Endocrinol 126 (1): 169-73, 1990; Wettergren A, et al., Dig Dis Sci
38 (4): 665-73, 1993). GLP-1[7-37], which has an additional glycine
residue at its carboxy terminus, also stimulates insulin secretion
in humans (Orskov, et al., Diabetes, 42:658-61, 1993). A
transmembrane G-protein adenylate-cyclase-coupled receptor believed
to be responsible for the insulinotropic effect of GLP-1 is
reported to have been cloned from a .beta.-cell line (Thorens,
Proc. Natl. Acad. Sci. USA 89:8641-45 (1992)).
[0005] Exendin-4 potently binds at GLP-1 receptors on
insulin-secreting .beta.TC1 cells, at dispersed acinar cells from
guinea pig pancreas, and at parietal cells from stomach; the
peptide is also said to stimulate somatostatin release and inhibit
gastrin release in isolated stomachs (Goke, et al., J. Biol. Chem.
268:19650-55, 1993; Schepp, et al., Eur. J. Pharmacol., 69:183-91,
1994; Eissele, et al., Life Sci., 55:629-34, 1994). Exendin-3 and
exendin-4 were reported to stimulate cAMP production in, and
amylase release from, pancreatic acinar cells (Malhotra, R., et
al., Regulatory Peptides, 41:149-56, 1992; Raufman, et al., J.
Biol. Chem. 267:21432-37, 1992; Singh, et al., Regul. Pept.
53:47-59, 1994). The use of exendin-3 and exendin-4 as
insulinotrophic agents for the treatment of diabetes mellitus and
the prevention of hyperglycemia has been proposed (Eng, U.S. Pat.
No. 5,424,286).
[0006] C-terminally truncated exendin peptides such as
exendin[9-39], a carboxyamidated molecule, and fragments 3-39
through 9-39 have been reported to be potent and selective
antagonists of GLP-1 (Goke, et al., J. Biol. Chem., 268:19650-55,
1993; Raufman, J. P., et al., J. Biol. Chem. 266:2897-902, 1991;
Schepp, W., et al., Eur. J. Pharm. 269:183-91, 1994;
Montrose-Rafizadeh, et al., Diabetes, 45(Suppl. 2):152A, 1996).
Exendin[9-39] is said to block endogenous GLP-1 in vivo, resulting
in reduced insulin secretion. Wang, et al., J. Clin. Invest.,
95:417-21, 1995; D'Alessio, et al., J. Clin. Invest., 97:133-38,
1996). The receptor apparently responsible for the insulinotropic
effect of GLP-1 has reportedly been cloned from rat pancreatic
islet cell (Thorens, B., Proc. Natl. Acad. Sci. USA 89:8641-8645,
1992). Exendins and exendin[9-39] are said to bind to the cloned
GLP-1 receptor (rat pancreatic .beta.-cell GLP-1 receptor (Fehmann
H C, et al., Peptides 15 (3): 453-6, 1994) and human GLP-1 receptor
(Thorens B, et al., Diabetes 42 (11): 1678-82, 1993). In cells
transfected with the cloned GLP-1 receptor, exendin-4 is reportedly
an agonist, i.e., it increases cAMP, while exendin[9-39] is
identified as an antagonist, i.e., it blocks the stimulatory
actions of exendin-4 and GLP-1. Id.
[0007] Exendin[9-39] is also reported to act as an antagonist of
the full length exendins, inhibiting stimulation of pancreatic
acinar cells by exendin-3 and exendin-4 (Raufman, et al., J. Biol.
Chem. 266:2897-902, 1991; Raufman, et al., J. Biol. Chem.,
266:21432-37, 1992). It is also reported that exendin[9-39]
inhibits the stimulation of plasma insulin levels by exendin-4, and
inhibits the somatostatin release-stimulating and gastrin
release-inhibiting activities of exendin-4 and GLP-1 (Kolligs, F.,
et al., Diabetes, 44:16-19, 1995; Eissele, et al., Life Sciences,
55:629-34, 1994).
[0008] Exendins have recently been found to inhibit gastric
emptying (U.S. Ser. No. 08/694,954, filed Aug. 8, 1996, which
enjoys common ownership with the present invention and is hereby
incorporated by reference).
[0009] Exendin [9-39] has been used to investigate the
physiological relevance of central GLP-1 in control of food intake
(Turton, M. D. et al. Nature 379:69-72, 1996). GLP-1 administered
by intracerebroventricular injection inhibits food intake in rats.
This satiety-inducing effect of GLP-1 delivered ICV is reported to
be inhibited by ICV injection of exendin [9-39] (Turton, supra).
However, it has been reported that GLP-1 does not inhibit food
intake in mice when administered by peripheral injection (Turton,
M. D., Nature 379:69-72, 1996; Bhaysar, S. P., Soc. Neurosci.
Abstr. 21:460 (188.8), 1995).
[0010] Obesity, excess adipose tissue, is becoming increasingly
prevalent in developed societies. For example, approximately 30% of
adults in the U.S. were estimated to be 20 percent above desirable
body weight--an accepted measure of obesity sufficient to impact a
health risk (Harrison's Principles of Internal Medicine 12th
Edition, McGraw Hill, Inc. (1991) p. 411). The pathogenesis of
obesity is believed to be multifactorial but the basic problem is
that in obese subjects food intake and energy expenditure do not
come into balance until there is excess adipose tissue. Attempts to
reduce food intake, or hypernutrition, are usually fruitless in the
medium term because the weight loss induced by dieting results in
both increased appetite and decreased energy expenditure (Leibel et
al., (1995) New England Journal of Medicine 322: 621-628). The
intensity of physical exercise required to expend enough energy to
materially lose adipose mass is too great for most people to
undertake on a sufficiently frequent basis. Thus, obesity is
currently a poorly treatable, chronic, essentially intractable
metabolic disorder. Not only is obesity itself believed by some to
be undesirable for cosmetic reasons, but obesity also carries
serious risk of co-morbidities including, Type 2 diabetes,
increased cardiac risk, hypertension, atherosclerosis, degenerative
arthritis, and increased incidence of complications of surgery
involving general anesthesia. Obesity due to hypernutrition is also
a risk factor for the group of conditions called insulin resistance
syndrome, or "syndrome X." In syndrome X, it has been reported that
there is a linkage between insulin resistance and hypertension.
(Watson N. and Sandler M., Curr. Med. Res. Opin., 12(6):374-378
(1991); Kodama J. et al., Diabetes Care, 13(11):1109-1111 (1990);
Lithell et al., J. Cardiovasc. Pharmacol., 15 Suppl. 5:S46-S52
(1990)).
[0011] In those few subjects who do succeed in losing weight, by
about 10 percent of body weight, there can be striking improvements
in co-morbid conditions, most especially Type 2 diabetes in which
dieting and weight loss are the primary therapeutic modality,
albeit relatively ineffective in many patients for the reasons
stated above. Reducing food intake in obese subjects would decrease
the plasma glucose level, the plasma lipid level, and the cardiac
risk in these subjects. Hypernutrition is also the result of, and
the psychological cause of, many eating disorders. Reducing food
intake would also be beneficial in the treatment of such
disorders.
[0012] Thus, it can be appreciated that an effective means to
reduce food intake is a major challenge and a superior method of
treatment would be of great utility. Such a method, and compounds
and compositions which are useful therefor, have been invented and
are described and claimed herein.
SUMMARY OF THE INVENTION
[0013] The present invention concerns the surprising discovery that
exendins and exendin agonists have a profound and prolonged effect
on inhibiting food intake.
[0014] The present invention is directed to novel methods for
treating conditions or disorders associated with hypernutrition,
comprising the administration of an exendin, for example, exendin-3
(SEQ ID NO:1, which is: His Ser Asp Gly Thr Phe Thr Ser Asp Leu Ser
Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser), or exendin-4 (SEQ ID
NO:2, which is: His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln
Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly
Pro Ser Ser Gly Ala Pro Pro Pro Ser), or other compounds which
effectively bind to the receptor at which exendin exerts its action
on reducing food intake. These methods will be useful in the
treatment of, for example, obesity, diabetes, including Type II or
non-insulin dependent diabetes, eating disorders, and
insulin-resistance syndrome.
[0015] In a first aspect, the invention features a method of
treating conditions or disorders which can be alleviated by
reducing food intake in a subject comprising administering to the
subject a therapeutically effective amount of an exendin or an
exendin agonist. By an "exendin agonist" is meant a compound that
mimics the effects of exendin on the reduction of food intake by
binding to the receptor or receptors where exendin causes this
effect. Preferred exendin agonist compounds include those described
in U.S. Provisional Patent Application Ser. No. 60/055,404,
entitled, "Novel Exendin Agonist Compounds," filed Aug. 8, 1997;
U.S. Provisional Patent Application Ser. No. 60/065,442, entitled,
"Novel Exendin Agonist Compounds," filed Nov. 14, 1997; and U.S.
Provisional Patent Application Ser. No. 60/066,029, entitled,
"Novel Exendin Agonist Compounds," filed Nov. 14, 1997; all of
which enjoy common ownership with the present application and all
of which are incorporated by this reference into the present
application as though fully set forth herein. By "condition or
disorder which can be alleviated by reducing food intake" is meant
any condition or disorder in a subject that is either caused by,
complicated by, or aggravated by a relatively high food intake, or
that can be alleviated by reducing food intake. Such conditions or
disorders include, but are not limited to, obesity, diabetes,
including Type II diabetes, eating disorders, and
insulin-resistance syndrome.
[0016] Thus, in a first embodiment, the present invention provides
a method for treating conditions or disorders which can be
alleviated by reducing food intake in a subject comprising
administering to said subject a therapeutically effective amount of
an exendin or an exendin agonist. Preferred exendin agonist
compounds include those described in U.S. Provisional Patent
Application Ser. Nos. 60/055,404; 60/065,442; and 60/066,029, which
have been incorporated by reference in the present application.
Preferably, the subject is a vertebrate, more preferably a mammal,
and most preferably a human. In preferred aspects, the exendin or
exendin agonist is administered parenterally, more preferably by
injection. In a most preferred aspect, the injection is a
peripheral injection. Preferably, about 10 .mu.g-30 .mu.g to about
5 mg of the exendin or exendin agonist is administered per day.
More preferably, about 10-30 .mu.g to about 2 mg, or about 10-30
.mu.g to about 1 mg of the exendin or exendin agonist is
administered per day. Most preferably, about 30 .mu.g to about 500
.mu.g of the exendin or exendin agonist is administered per
day.
[0017] In various preferred embodiments of the invention, the
condition or disorder is obesity, diabetes, preferably Type II
diabetes, an eating disorder, or insulin-resistance syndrome.
[0018] In other preferred aspects of the invention, a method is
provided for reducing the appetite of a subject comprising
administering to said subject an appetite-lowering amount of an
exendin or an exendin agonist.
[0019] In yet other preferred aspects, a method is provided for
lowering plasma lipids comprising administering to said subject a
therapeutically effective amount of an exendin or an exendin
agonist.
[0020] The methods of the present invention may also be used to
reduce the cardiac risk of a subject comprising administering to
said subject a therapeutically effective amount of an exendin or an
exendin agonist. In one preferred aspect, the exendin or exendin
agonist used in the methods of the present invention is exendin-3.
In another preferred aspect, said exendin is exendin-4. Other
preferred exendin agonists include exendin-4 (1-30) (SEQ ID NO:6,
which is His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly),
exendin-4 (1-30) amide (SEQ ID NO:7, which is His Gly Glu Gly Thr
Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe
Ile Glu Trp Leu Lys Asn Gly Gly-NH.sub.2), exendin-4 (1-28) amide
(SEQ ID NO:40, which is His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser
Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys
Asn-NH.sub.2), .sup.14Leu, .sup.25Phe exendin-4 amide (SEQ ID NO:9,
which is His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly Pro
Ser Ser Gly Ala Pro Pro Pro Ser-NH.sub.2), .sup.14Leu, .sup.25Phe
exendin-4 (1-28) amide (SEQ ID NO:41, which is His Gly Glu Gly Thr
Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn-NH.sub.2), and .sup.14Leu, .sup.22Ala,
.sup.25Phe exendin-4 (1-28) amide (SEQ ID NO:8, which is His Gly
Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val
Arg Leu Ala Ile Glu Phe Leu Lys Asn-NH.sub.2).
[0021] In the methods of the present invention, the exendins and
exendin agonists may be administered separately or together with
one or more other compounds and compositions that exhibit a long
term or short-term satiety action, including, but not limited to
other compounds and compositions that comprise an amylin agonist,
cholecystokinin (CCK), or a leptin (ob protein). Suitable amylin
agonists include, for example, [.sup.25,28,29Pro-]-human amylin
(also known as "pramlintide," and previously referred to as
"AC-137") as described in "Amylin Agonist Peptides and Uses
Therefor," U.S. Pat. No. 5,686,511, issued Nov. 11, 1997, and
salmon calcitonin. The CCK used is preferably CCK octopeptide
(CCK-8). Leptin is discussed in, for example, Pelleymounter, M. A.,
et al. Science 269:540-43 (1995); Halaas, J. L., et al. Science
269:543-46 (1995); and Campfield, L. A., et al. Eur. J. Pharmac.
262:133-41 (1994).
[0022] In other embodiments of the invention is provided a
pharmaceutical composition for use in the treatment of conditions
or disorders which can be alleviated by reducing food intake
comprising a therapeutically effective amount of an exendin or
exendin agonist in association with a pharmaceutically acceptable
carrier. Preferably, the pharmaceutical composition comprises a
therapeutically effective amount for a human subject.
[0023] The pharmaceutical composition may preferably be used for
reducing the appetite of a subject, reducing the weight of a
subject, lowering the plasma lipid level of a subject, or reducing
the cardiac risk of a subject. Those of skill in the art will
recognize that the pharmaceutical composition will preferably
comprise a therapeutically effective amount of an exendin or
exendin agonist to accomplish the desired effect in the
subject.
[0024] The pharmaceutical compositions may further comprise one or
more other compounds and compositions that exhibit a long-term or
short-term satiety action, including, but not limited to other
compounds and compositions that comprise an amylin agonist, CCK,
preferably CCK-8, or leptin. Suitable amylin agonists include, for
example, [.sup.25,28,29Pro]-human amylin and salmon calcitonin.
[0025] In one preferred aspect, the pharmaceutical composition
comprises exendin-3. In another preferred aspect, the
pharmaceutical composition comprises exendin-4. In other preferred
aspects, the pharmaceutical compositions comprises a peptide
selected from: exendin-4 (1-30), exendin-4 (1-30) amide, exendin-4
(1-28) amide, .sup.14Leu,.sup.25Phe exendin-4 amide,
.sup.14Leu,.sup.25Phe exendin-4 (1-28) amide, and
.sup.14Leu,.sup.22Ala,.sup.25Phe exendin-4 (1-28) amide.
BRIEF DESCRIPTION OF THE DRAWINGS
[0026] FIG. 1 is a graphical depiction of the change of food intake
in normal mice after intraperitoneal injection of exendin-4 and
GLP-1.
[0027] FIG. 2 is a graphical depiction of the change of food intake
in obese mice after intraperitoneal injection of exendin-4.
[0028] FIG. 3 is a graphical depiction of the change of food intake
in rats after intracerebroventricular injection of exendin-4
[0029] FIG. 4 is a graphical depiction of the change of food intake
in normal mice after intraperitoneal injection of exendin-4 (1-30)
("Compound 1").
[0030] FIG. 5 is a graphical depiction of the change of food intake
in normal mice after intraperitoneal injection of exendin-4 (1-30)
amide ("Compound 2").
[0031] FIG. 6 is a graphical depiction of the change of food intake
in normal mice after intraperitoneal injection of exendin-4 (1-28)
amide ("Compound 3").
[0032] FIG. 7 is a graphical depiction of the change of food intake
in normal mice after intraperitoneal injection of
.sup.14Leu,.sup.25Phe exendin-4 amide ("Compound 4").
[0033] FIG. 8 is a graphical depiction of the change of food intake
in normal mice after intraperitoneal injection of
.sup.14Leu,.sup.25Phe exendin-4 (1-28) amide ("Compound 5").
[0034] FIG. 9 is a graphical depiction of the change of food intake
in normal mice after intraperitoneal injection of
.sup.14Leu,.sup.22Ala,.sup.25Phe exendin-4 (1-28) amide ("Compound
6").
[0035] FIG. 10 depicts the amino acid sequences for certain exendin
agonist compounds useful in the present invention (SEQ ID
NOs:9-39).
DETAILED DESCRIPTION OF THE INVENTION
[0036] Exendins and exendin agonists are useful as described herein
in view of their pharmacological properties. Activity as exendin
agonists can be indicated by activity in the assays described
below. Effects of exendins or exendin agonists on reducing food
intake can be identified, evaluated, or screened for, using the
methods described in the Examples below, or other methods known in
the art for determining effects on food intake or appetite.
Exendin Agonist Compounds
[0037] Exendin agonist compounds are those described in U.S.
Provisional Application No. 60/055,404, including compounds of the
formula (I) (SEQ ID NO:3):
TABLE-US-00001 1 5 10 Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Gly Thr
Xaa.sub.4 Xaa.sub.5 Xaa.sub.6 Xaa.sub.7 Xaa.sub.8 15 20 Ser Lys Gln
Xaa.sub.9 Glu Glu Glu Ala Val Arg Leu 25 30 Xaa.sub.10 Xaa.sub.11
Xaa.sub.12 Xaa.sub.13 Leu Lys Asn Gly Gly Xaa.sub.14 35 Ser Ser Gly
Ala Xaa.sub.15 Xaa.sub.16 Xaa.sub.17 Xaa.sub.18-Z
[0038] wherein Xaa.sub.1 is His, Arg or Tyr; Xaa.sub.2 is Ser, Gly,
Ala or Thr; Xaa.sub.3 is Asp or Glu; Xaa.sub.4 is Phe, Tyr or
naphthylalanine; Xaa.sub.5 is Thr or Ser; Xaa.sub.6 is Ser or Thr;
Xaa.sub.7 is Asp or Glu; Xaa.sub.8 is Leu, Ile, Val, pentylglycine
or Met; Xaa.sub.9 is Leu, Ile, pentylglycine, Val or Met;
Xaa.sub.10 is Phe, Tyr or naphthylalanine; Xaa.sub.11 is Ile, Val,
Leu, pentylglycine, tert-butylglycine or Met; Xaa.sub.12 is Glu or
Asp; Xaa.sub.13 is Trp, Phe, Tyr, or naphthylalanine; Xaa.sub.14,
Xaa.sub.15, Xaa.sub.16 and Xaa.sub.17 are independently Pro,
homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine,
N-alkylpentylglycine or N-alkylalanine; Xaa.sub.18 is Ser, Thr or
Tyr; and Z is --OH or --NH.sub.2; with the proviso that the
compound is not exendin-3 or exindin-4.
[0039] Preferred N-alkyl groups for N-alkylglycine,
N-alkylpentylglycine and N-alkylalanine include lower alkyl groups
preferably of 1 to about 6 carbon atoms, more preferably of 1 to 4
carbon atoms. Suitable compounds include those listed in FIG. 10
A-B having amino acid sequences of the formula of SEQ ID NO:3,
including those of SEQ ID NOs:9 to 39.
[0040] Preferred exendin agonist compounds include those wherein
Xaa.sub.1 is His or Tyr. More preferably Xaa.sub.1 is His.
Preferred are those compounds wherein Xaa.sub.2 is Gly. Preferred
are those compounds wherein Xaa.sub.9 is Leu, pentylglycine or Met.
Preferred compounds include those wherein Xaa.sub.13 is Trp or Phe.
Also preferred are compounds where Xaa.sub.4 is Phe or
naphthylalanine; Xaa.sub.11 is Ile or Val and Xaa.sub.14,
Xaa.sub.15, Xaa.sub.16 and Xaa.sub.17 are independently selected
from Pro, homoproline, thioproline or N-alkylalanine. Preferably
N-alkylalanine has a N-alkyl group of 1 to about 6 carbon atoms.
According to an especially preferred aspect, Xaa.sub.15, Xaa.sub.16
and Xaa.sub.17 are the same amino acid reside. Preferred are
compounds wherein Xaa.sub.18 is Ser or Tyr, more preferably Ser.
Preferably Z is --NH.sub.2.
[0041] According to one aspect, preferred are compounds of formula
(I) wherein Xaa.sub.1 is His or Tyr, more preferably His; Xaa.sub.2
is Gly; Xaa.sub.4 is Phe or naphthylalanine; Xaa.sub.9 is Leu,
pentylglycine or Met; Xaa.sub.10 is Phe or naphthylalanine;
Xaa.sub.11 is Ile or Val; Xaa.sub.14, Xaa.sub.15, Xaa.sub.16 and
Xaa.sub.17 are independently selected from Pro, homoproline,
thioproline or N-alkylalanine; and Xaa.sub.18 is Ser or Tyr, more
preferably Ser. More preferably Z is --NH.sub.2.
[0042] According to an especially preferred aspect, especially
preferred compounds include those of formula (I) wherein: Xaa.sub.1
is His or Arg; Xaa.sub.2 is Gly; Xaa.sub.3 is Asp or Glu; Xaa.sub.4
is Phe or napthylalanine; Xaa.sub.5 is Thr or Ser; Xaa.sub.6 is Ser
or Thr; Xaa.sub.7 is Asp or Glu; Xaa.sub.8 is Leu or pentylglycine;
Xaa.sub.9 is Leu or pentylglycine; Xaa.sub.10 is Phe or
naphthylalanine; Xaa.sub.11 is Ile, Val or t-butyltylglycine;
Xaa.sub.12 is Glu or Asp; Xaa.sub.13 is Trp or Phe; Xaa.sub.14,
Xaa.sub.15, Xaa.sub.16, and Xaa.sub.17 are independently Pro,
homoproline, thioproline, or N-methylalanine; Xaa.sub.18 is Ser or
Tyr: and Z is --OH or --NH.sub.2; with the proviso that the
compound does not have the formula of either SEQ ID NOs:1 or 2.
More preferably Z is --NH.sub.2. Especially preferred compounds
include those having the amino acid sequence of SEQ ID NOs:9, 10,
21, 22, 23, 26, 28, 34, 35 and 39.
[0043] According to an especially preferred aspect, provided are
compounds where Xaa.sub.9 is Leu, Ile, Val or pentylglycine, more
preferably Leu or pentylglycine, and Xaa.sub.13 is Phe, Tyr or
naphthylalanine, more preferably Phe or naphthylalanine. These
compounds will exhibit advantageous duration of action and be less
subject to oxidative degradation, both in vitro and in vivo, as
well as during synthesis of the compound.
[0044] Exendin agonist compounds also include those described in
U.S. Provisional Application No. 60/065,442, including compounds of
the formula (II) (SEQ ID NO:4):
TABLE-US-00002 Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Gly Xaa.sub.5
Xaa.sub.6 Xaa.sub.7 Xaa.sub.8 Xaa.sub.9 Xaa.sub.10 Xaa.sub.11
Xaa.sub.12 Xaa.sub.13 Xaa.sub.14 Xaa.sub.15 Xaa.sub.16 Xaa.sub.17
Ala Xaa.sub.19 Xaa.sub.20 Xaa.sub.21 Xaa.sub.22 Xaa.sub.23
Xaa.sub.24 Xaa.sub.25 Xaa.sub.26 Xaa.sub.27 Xaa.sub.28-Z.sub.1;
[0045] wherein Xaa.sub.1 is His, Arg or Tyr; Xaa.sub.2 is Ser, Gly,
Ala or Thr; Xaa.sub.3 is Asp or Glu; Xaa.sub.5 is Ala or Thr;
Xaa.sub.6 is Ala, Phe, Tyr or naphthylalanine; Xaa.sub.7 is Thr or
Ser; Xaa.sub.8 is Ala, Ser or Thr; Xaa.sub.9 is Asp or Glu;
Xaa.sub.10 is Ala, Leu, Ile, Val, pentylglycine or Met; Xaa.sub.11
is Ala or Ser; Xaa.sub.12 is Ala or Lys; Xaa.sub.13 is Ala or Gln;
Xaa.sub.14 is Ala, Leu, Ile, pentylglycine, Val or Met; Xaa.sub.15
is Ala or Glu; Xaa.sub.16 is Ala or Glu; Xaa.sub.17 is Ala or Glu;
Xaa.sub.19 is Ala or Val; Xaa.sub.20 is Ala or Arg; Xaa.sub.21 is
Ala or Leu; Xaa.sub.22 is Ala, Phe, Tyr or naphthylalanine;
Xaa.sub.23 is Ile, Val, Leu, pentylglycine, tert-butylglycine or
Met; Xaa.sub.24 is Ala, Glu or Asp; Xaa.sub.25 is Ala, Tip, Phe,
Tyr or naphthylalanine; Xaa.sub.26 is Ala or Leu; Xaa.sub.27 is Ala
or Lys; Xaa.sub.28 is Ala or Asn; Z.sub.1 is --OH, NH.sub.2,
Gly-Z.sub.2, Gly Gly-Z.sub.2, Gly Gly Xaa.sub.31-Z.sub.2, Gly Gly
Xaa.sub.31 Ser-Z.sub.2, Gly Gly Xaa.sub.31 Ser Ser-Z.sub.2, Gly Gly
Xaa.sub.31 Ser Ser Gly-Z.sub.2, Gly Gly Xaa.sub.31 Ser Ser Gly
Ala-Z.sub.2, Gly Gly Xaa.sub.31 Ser Ser Gly Ala Xaa.sub.36-Z.sub.2,
Gly Gly Xaa.sub.31 Ser Ser Gly Ala Xaa.sub.36 Xaa.sub.37-Z.sub.2 or
Gly Gly Xaa.sub.31 Ser Ser Gly Ala Xaa.sub.36 Xaa.sub.37
Xaa.sub.38-Z.sub.2; Xaa.sub.31, Xaa.sub.36, Xaa.sub.37 and
Xaa.sub.38 are independently Pro, homoproline, 3Hyp, 4Hyp,
thioproline, N-alkylglycine, N-alkylpentylglycine or
N-alkylalanine; and Z.sub.2 is --OH or --NH.sub.2; provided that no
more than three of Xaa.sub.3, Xaa.sub.5, Xaa.sub.6, Xaa.sub.8,
Xaa.sub.10, Xaa.sub.11, Xaa.sub.12, Xaa.sub.13, Xaa.sub.14,
Xaa.sub.15, Xaa.sub.16, Xaa.sub.17, Xaa.sub.19, Xaa.sub.20,
Xaa.sub.21, Xaa.sub.24, Xaa.sub.25, Xaa.sub.26, Xaa.sub.27 and
Xaa.sub.28 are Ala.
[0046] Preferred N-alkyl groups for N-alkylglycine,
N-alkylpentylglycine and N-alkylalanine include lower alkyl groups
preferably of 1 to about 6 carbon atoms, more preferably of 1 to 4
carbon atoms. Preferred exendin agonist compounds include those
wherein Xaa.sub.1 is His or Tyr. More preferably Xaa.sub.1 is His.
Preferred are those compounds wherein Xaa.sub.2 is Gly. Preferred
are those compounds wherein Xaa.sub.14 is Leu, pentylglycine or
Met. Preferred compounds are those wherein Xaa.sub.25 is Trp or
Phe. Preferred compounds are those where Xaa.sub.6 is Phe or
naphthylalanine; Xaa.sub.22 is Phe or naphthylalanine and
Xaa.sub.23 is Ile or Val. Preferred are compounds wherein
Xaa.sub.31, Xaa.sub.36, Xaa.sub.37 and Xaa.sub.38 are independently
selected from Pro, homoproline, thioproline and N-alkylalanine.
Preferably Z.sub.1 is --NH.sub.2. Preferable Z.sub.2 is
--NH.sub.2.
[0047] According to one aspect, preferred are compounds of formula
(II) wherein Xaa.sub.1 is His or Tyr, more preferably His;
Xaa.sub.2 is Gly; Xaa.sub.6 is Phe or naphthylalanine; Xaa.sub.14
is Leu, pentylglycine or Met; Xaa.sub.22 is Phe or naphthylalanine;
Xaa.sub.23 is Ile or Val; Xaa.sub.31, Xaa.sub.36, Xaa.sub.37 and
Xaa.sub.38 are independently selected from Pro, homoproline,
thioproline or N-alkylalanine More preferably Z.sub.1 is
--NH.sub.2.
[0048] According to an especially preferred aspect, especially
preferred compounds include those of formula (II) wherein:
Xaa.sub.1 is His or Arg; Xaa.sub.2 is Gly or Ala; Xaa.sub.3 is Asp
or Glu; Xaa.sub.5 is Ala or Thr; Xaa.sub.6 is Ala, Phe or
naphthylalanine; Xaa.sub.7 is Thr or Ser; Xaa.sub.8 is Ala, Ser or
Thr; Xaa.sub.9 is Asp or Glu; Xaa.sub.10 is Ala, Leu or
pentylglycine; Xaa.sub.11 is Ala or Ser; Xaa.sub.12 is Ala or Lys;
Xaa.sub.13 is Ala or Gln; Xaa.sub.14 is Ala, Leu or pentylglycine;
Xaa.sub.15 is Ala or Glu; Xaa.sub.16 is Ala or Glu; Xaa.sub.17 is
Ala or Glu; Xaa.sub.19 is Ala or Val; Xaa.sub.20 is Ala or Arg;
Xaa.sub.21 is Ala or Leu; Xaa.sub.22 is Phe or naphthylalanine;
Xaa.sub.23 is Ile, Val or tert-butylglycine; Xaa.sub.24 is Ala, Glu
or Asp; Xaa.sub.25 is Ala, Trp or Phe; Xaa.sub.26 is Ala or Leu;
Xaa.sub.27 is Ala or Lys; Xaa.sub.28 is Ala or Asn; Z.sub.1 is
--OH, --NH.sub.2, Gly-Z.sub.2, Gly Gly-Z.sub.2, Gly Gly
Xaa.sub.31-Z.sub.2, Gly Gly Xaa.sub.31 Ser-Z.sub.2, Gly Gly
Xaa.sub.31 Ser Ser-Z.sub.2, Gly Gly Xaa.sub.31 Ser Ser Gly-Z.sub.2,
Gly Gly Xaa.sub.31 Ser Ser Gly Ala-Z.sub.2, Gly Gly Xaa.sub.31 Ser
Ser Gly Ala Xaa.sub.36-Z.sub.2, Gly Gly Xaa.sub.31 Ser Ser Gly Ala
Xaa.sub.36 Xaa.sub.37-Z.sub.2, Gly Gly Xaa.sub.31 Ser Ser Gly Ala
Xaa.sub.36 Xaa.sub.37 Xaa.sub.38-Z.sub.2; Xaa.sub.31, Xaa.sub.36,
Xaa.sub.37 and Xaa.sub.38 being independently Pro homoproline,
thioproline or N-methylalanine; and Z.sub.2 being --OH or
--NH.sub.2; provided that no more than three of Xaa.sub.3,
Xaa.sub.5, Xaa.sub.6, Xaa.sub.8, Xaa.sub.10, Xaa.sub.11,
Xaa.sub.12, Xaa.sub.13, Xaa.sub.14, Xaa.sub.15, Xaa.sub.16,
Xaa.sub.17, Xaa.sub.19, Xaa.sub.20, Xaa.sub.21, Xaa.sub.24,
Xaa.sub.25, Xaa.sub.26, Xaa.sub.27 and Xaa.sub.28 are Ala.
Especially preferred compounds include those having the amino acid
sequence of SEQ ID NOs:40-61.
[0049] According to an especially preferred aspect, provided are
compounds where Xaa.sub.14 is Leu, Ile, Val or pentylglycine, more
preferably Leu or pentylglycine, and Xaa.sub.25 is Phe, Tyr or
naphthylalanine, more preferably Phe or naphthylalanine. These
compounds will be less susceptive to oxidative degradation, both in
vitro and in vivo, as well as during synthesis of the compound.
[0050] Exendin agonist compounds also include those described in
U.S. Provisional Application No. 60/066,029, including compounds of
the formula (III) (SEQ ID NO:5):
TABLE-US-00003 Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5
Xaa.sub.6 Xaa.sub.7 Xaa.sub.8 Xaa.sub.9 Xaa.sub.10 Xaa.sub.11
Xaa.sub.12 Xaa.sub.13 Xaa.sub.14 Xaa.sub.15 Xaa.sub.16 Xaa.sub.17
Ala Xaa.sub.19 Xaa.sub.20 Xaa.sub.21 Xaa.sub.22 Xaa.sub.23
Xaa.sub.24 Xaa.sub.25 Xaa.sub.26 Xaa.sub.27 Xaa.sub.28-Z.sub.1;
[0051] wherein Xaa.sub.1 is His, Arg, Tyr, Ala, Norval, Val or
Norleu; Xaa.sub.2 is Ser, Gly, Ala or Thr; Xaa.sub.3 is Ala, Asp or
Glu; Xaa.sub.4 is Ala, Norval, Val, Norleu or Gly; Xaa.sub.5 is Ala
or Thr; Xaa.sub.6 is Phe, Tyr or naphthylalanine; Xaa.sub.7 is Thr
or Ser; Xaa.sub.8 is Ala, Ser or Thr; Xaa.sub.9 is Ala, Norval,
Val, Norleu, Asp or Glu; Xaa.sub.10 is Ala, Leu, Ile, Val,
pentylglycine or Met; Xaa.sub.11 is Ala or Ser; Xaa.sub.12 is Ala
or Lys; Xaa.sub.13 is Ala or Gln; Xaa.sub.14 is Ala, Leu, Ile,
pentylglycine, Val or Met; Xaa.sub.15 is Ala or Glu; Xaa.sub.16 is
Ala or Glu; Xaa.sub.17 is Ala or Glu; Xaa.sub.19 is Ala or Val;
Xaa.sub.20 is Ala or Arg; Xaa.sub.21 is Ala or Leu; Xaa.sub.22 is
Phe, Tyr or naphthylalanine; Xaa.sub.23 is Ile, Val, Leu,
pentylglycine, tert-butylglycine or Met; Xaa.sub.24 is Ala, Glu or
Asp; Xaa.sub.25 is Ala, Trp, Phe, Tyr or naphthylalanine;
Xaa.sub.26 is Ala or Leu; Xaa.sub.27 is Ala or Lys; Xaa.sub.28 is
Ala or Asn; Z.sub.1 is --OH, NH.sub.2, Gly-Z.sub.2, Gly
Gly-Z.sub.2, Gly Gly Xaa.sub.31-Z.sub.2, Gly Gly Xaa.sub.31
Ser-Z.sub.2, Gly Gly Xaa.sub.31 Ser Ser-Z.sub.2, Gly Gly Xaa.sub.31
Ser Ser Gly-Z.sub.2, Gly Gly Xaa.sub.31 Ser Ser Gly Ala-Z.sub.2,
Gly Gly Xaa.sub.31 Ser Ser Gly Ala Xaa.sub.36-Z.sub.2, Gly Gly
Xaa.sub.31 Ser Ser Gly Ala Xaa.sub.36 Xaa.sub.37-Z.sub.2, Gly Gly
Xaa.sub.31 Ser Ser Gly Ala Xaa.sub.36 Xaa.sub.37 Xaa.sub.38-Z.sub.2
or Gly Gly Xaa.sub.31 Ser Ser Gly Ala Xaa.sub.36 Xaa.sub.37
Xaa.sub.38 Xaa.sub.39-Z.sub.2; wherein Xaa.sub.31, Xaa.sub.36,
Xaa.sub.37 and Xaa.sub.38 are independently Pro, homoproline, 3Hyp,
4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine or
N-alkylalanine; and Z.sub.2 is --OH or --NH.sub.2; provided that no
more than three of Xaa.sub.3, Xaa.sub.4, Xaa.sub.5, Xaa.sub.6,
Xaa.sub.8, Xaa.sub.9, Xaa.sub.10, Xaa.sub.11, Xaa.sub.12,
Xaa.sub.13, Xaa.sub.14, Xaa.sub.15, Xaa.sub.16, Xaa.sub.17,
Xaa.sub.19, Xaa.sub.20, Xaa.sub.21, Xaa.sub.24, Xaa.sub.25,
Xaa.sub.26, Xaa.sub.27 and Xaa.sub.28 are Ala; and provided also
that, if Xaa.sub.1 is His, Arg or Tyr, then at least one of
Xaa.sub.3, Xaa.sub.4 and Xaa.sub.9 is Ala.
DEFINITIONS
[0052] In accordance with the present invention and as used herein,
the following terms are defined to have the following meanings,
unless explicitly stated otherwise.
[0053] The term "amino acid" refers to natural amino acids,
unnatural amino acids, and amino acid analogs, all in their D and L
stereoisomers if their structure allow such stereoisomeric forms.
Natural amino acids include alanine (Ala), arginine (Arg),
asparagine (Asn), aspartic acid (Asp), cysteine (Cys), glutamine
(Gln), glutamic acid (Glu), glycine (Gly), histidine (His),
isoleucine (Ile), leucine (Leu), Lysine (Lys), methionine (Met),
phenylalanine (Phe), proline (Pro), serine (Ser), threonine (Thr),
tryptophan (Trp), tyrosine (Tyr) and valine (Val). Unnatural amino
acids include, but are not limited to azetidinecarboxylic acid,
2-aminoadipic acid, 3-aminoadipic acid, beta-alanine,
aminopropionic acid, 2-aminobutyric acid, 4-aminobutyric acid,
6-aminocaproic acid, 2-aminoheptanoic acid, 2-aminoisobutyric acid,
3-aminoisbutyric acid, 2-aminopimelic acid, tertiary-butylglycine,
2,4-diaminoisobutyric acid, desmosine, 2,2'-diaminopimelic acid,
2,3-diaminopropionic acid, N-ethylglycine, N-ethylasparagine,
homoproline, hydroxylysine, allo-hydroxylysine, 3-hydroxyproline,
4-hydroxyproline, isodesmosine, allo-isoleucine, N-methylalanine,
N-methylglycine, N-methylisoleucine, N-methylpentylglycine,
N-methylvaline, naphthalanine, norvaline, norleucine, ornithine,
pentylglycine, pipecolic acid and thioproline. Amino acid analogs
include the natural and unnatural amino acids which are chemically
blocked, reversibly or irreversibly, or modified on their
N-terminal amino group or their side-chain groups, as for example,
methionine sulfoxide, methionine sulfone,
S-(carboxymethyl)-cysteine, S-(carboxymethyl)-cysteine sulfoxide
and S-(carboxymethyl)-cysteine sulfone.
[0054] The term "amino acid analog" refers to an amino acid wherein
either the C-terminal carboxy group, the N-terminal amino group or
side-chain functional group has been chemically codified to another
functional group. For example, aspartic acid-(beta-methyl ester) is
an amino acid analog of aspartic acid; N-ethylglycine is an amino
acid analog of glycine; or alanine carboxamide is an amino acid
analog of alanine.
[0055] The term "amino acid residue" refers to radicals having the
structure: (1) --C(O)--R--NH--, wherein R typically is --CH(R')--,
wherein R' is an amino acid side chain, typically H or a carbon
containing substituent; or (2),
##STR00001##
wherein p is 1, 2 or 3 representing the azetidinecarboxylic acid,
proline or pipecolic acid residues, respectively.
[0056] The term "lower" referred to herein in connection with
organic radicals such as alkyl groups defines such groups with up
to and including about 6, preferably up to and including 4 and
advantageously one or two carbon atoms. Such groups may be straight
chain or branched chain.
[0057] "Pharmaceutically acceptable salt" includes salts of the
compounds described herein derived from the combination of such
compounds and an organic or inorganic acid. In practice the use of
the salt form amounts to use of the base form. The compounds are
useful in both free base and salt form.
[0058] In addition, the following abbreviations stand for the
following: "ACN" or "CH.sub.3CN" refers to acetonitrile. "Boc",
"tBoc" or "Tboc" refers to t-butoxy carbonyl. "DCC" refers to
N,N'-dicyclohexylcarbodiimide. "Fmoc" refers to
fluorenylmethoxycarbonyl. "HBTU" refers to
2-(1H-benzotriazol-1-yl)-1,1,3,3,-tetramethyluronium
hexafluorophosphate. "HOBt" refers to 1-hydroxybenzotriazole
monohydrate. "homoP" or hPro" refers to homoproline. "MeAla" or
"Nme" refers to N-methylalanine "naph" refers to naphthylalanine
"pG" or "pGly" refers to pentylglycine. "tBuG" refers to
tertiary-butylglycine. "ThioP" or tPro" refers to thioproline.
"3Hyp" refers to 3-hydroxyproline. "4Hyp" refers to
4-hydroxyproline. NAG" refers to N-alkylglycine. "NAPG" refers to
N-alkylpentylglycine. "Norval" refers to norvaline. "Norleu" refers
to norleucine.
Preparation of Compounds
[0059] The exendins and exendin agonists described herein may be
prepared using standard solid-phase peptide synthesis techniques
and preferably an automated or semiautomated peptide synthesizer.
Typically, using such techniques, an -N-carbamoyl protected amino
acid and an amino acid attached to the growing peptide chain on a
resin are coupled at room temperature in an inert solvent such as
dimethylformamide, N-methylpyrrolidinone or methylene chloride in
the presence of coupling agents such as dicyclohexylcarbodiimide
and 1-hydroxybenzotriazole in the presence of a base such as
diisopropylethylamine. The -N-carbamoyl protecting group is removed
from the resulting peptide-resin using a reagent such as
trifluoroacetic acid or piperidine, and the coupling reaction
repeated with the next desired N-protected amino acid to be added
to the peptide chain. Suitable N-protecting groups are well known
in the art, with t-butyloxycarbonyl (tBoc) and
fluorenylmethoxycarbonyl (Fmoc) being preferred herein.
[0060] The solvents, amino acid derivatives and
4-methylbenzhydryl-amine resin used in the peptide synthesizer may
be purchased from Applied Biosystems Inc. (Foster City, Calif.).
The following side-chain protected amino acids may be purchased
from Applied Biosystems, Inc.: Boc-Arg(Mts), Fmoc-Arg(Pmc),
Boc-Thr(Bzl), Fmoc-Thr(t-Bu), Boc-Ser(Bzl), Fmoc-Ser(t-Bu),
Boc-Tyr(BrZ), Fmoc-Tyr(t-Bu), Boc-Lys(Cl-Z), Fmoc-Lys(Boc),
Boc-Glu(Bzl), Fmoc-Glu(t-Bu), Fmoc-His(Trt), Fmoc-Asn(Trt), and
Fmoc-Gln(Trt). Boc-His(BOM) may be purchased from Applied
Biosystems, Inc. or Bachem Inc. (Torrance, Calif.). Anisole,
dimethylsulfide, phenol, ethanedithiol, and thioanisole may be
obtained from Aldrich Chemical Company (Milwaukee, Wis.). Air
Products and Chemicals (Allentown, Pa.) supplies HF. Ethyl ether,
acetic acid and methanol may be purchased from Fisher Scientific
(Pittsburgh, Pa.).
[0061] Solid phase peptide synthesis may be carried out with an
automatic peptide synthesizer (Model 430A, Applied Biosystems Inc.,
Foster City, Calif.) using the NMP/HOBt (Option 1) system and tBoc
or Fmoc chemistry (see, Applied Biosystems User's Manual for the
ABI 430A Peptide Synthesizer, Version 1.3B Jul. 1, 1988, section 6,
pp. 49-70, Applied Biosystems, Inc., Foster City, Calif.) with
capping. Boc-peptide-resins may be cleaved with HF (-5.degree. C.
to 0.degree. C., 1 hour). The peptide may be extracted from the
resin with alternating water and acetic acid, and the filtrates
lyophilized. The Fmoc-peptide resins may be cleaved according to
standard methods (Introduction to Cleavage Techniques, Applied
Biosystems, Inc., 1990, pp. 6-12). Peptides may be also be
assembled using an Advanced Chem Tech Synthesizer (Model MPS 350,
Louisville, Ky.).
[0062] Peptides may be purified by RP-HPLC (preparative and
analytical) using a Waters Delta Prep 3000 system. A C4, C8 or C18
preparative column (10.mu., 2.2.times.25 cm; Vydac, Hesperia,
Calif.) may be used to isolate peptides, and purity may be
determined using a C4, C8 or C18 analytical column (5.mu.,
0.46.times.25 cm; Vydac). Solvents (A=0.1% TFA/water and B=0.1%
TFA/CH.sub.3CN) may be delivered to the analytical column at a
flowrate of 1.0 ml/min and to the preparative column at 15 ml/min.
Amino acid analyses may be performed on the Waters Pico Tag system
and processed using the Maxima program. Peptides may be hydrolyzed
by vapor-phase acid hydrolysis (115.degree. C., 20-24 h).
Hydrolysates may be derivatized and analyzed by standard methods
(Cohen, et al., The Pico Tag Method: A Manual of Advanced
Techniques for Amino Acid Analysis, pp. 11-52, Millipore
Corporation, Milford, Mass. (1989)). Fast atom bombardment analysis
may be carried out by M-Scan, Incorporated (West Chester, Pa.).
Mass calibration may be performed using cesium iodide or cesium
iodide/glycerol. Plasma desorption ionization analysis using time
of flight detection may be carried out on an Applied Biosystems
Bio-Ion 20 mass spectrometer. Electrospray mass spectroscopy may be
carried out on a VG-Trio machine.
[0063] Peptide compounds useful in the invention may also be
prepared using recombinant DNA techniques, using methods now known
in the art. See, e.g., Sambrook et al., Molecular Cloning: A
Laboratory Manual, 2d Ed., Cold Spring Harbor (1989). Non-peptide
compounds useful in the present invention may be prepared by
art-known methods. For example, phosphate-containing amino acids
and peptides containing such amino acids, may be prepared using
methods known in the art. See, e.g., Bartlett and Landen, Biorg.
Chem. 14:356-377 (1986).
[0064] The compounds described above are useful in view of their
pharmacological properties. In particular, the compounds of the
invention possess activity as agents to reduce food intake. They
can be used to treat conditions or diseases which can be alleviated
by reducing food intake.
[0065] Compositions useful in the invention may conveniently be
provided in the form of formulations suitable for parenteral
(including intravenous, intramuscular and subcutaneous) or nasal or
oral administration. In some cases, it will be convenient to
provide an exendin or exendin agonist and another
food-intake-reducing, plasma glucose-lowering or plasma
lipid-lowering agent, such as amylin, an amylin agonist, a CCK, or
a leptin, in a single composition or solution for administration
together. In other cases, it may be more advantageous to administer
the additional agent separately from said exendin or exendin
agonist. A suitable administration format may best be determined by
a medical practitioner for each patient individually. Suitable
pharmaceutically acceptable carriers and their formulation are
described in standard formulation treatises, e.g., Remington's
Pharmaceutical Sciences by E. W. Martin. See also Wang, Y. J. and
Hanson, M. A. "Parenteral Formulations of Proteins and Peptides:
Stability and Stabilizers," Journal of Parenteral Science and
Technology, Technical Report No. 10, Supp. 42:2 S (1988).
[0066] Compounds useful in the invention can be provided as
parenteral compositions for injection or infusion. They can, for
example, be suspended in an inert oil, suitably a vegetable oil
such as sesame, peanut, olive oil, or other acceptable carrier.
Preferably, they are suspended in an aqueous carrier, for example,
in an isotonic buffer solution at a pH of about 3.0 to 8.0,
preferably at a pH of about 3.5 to 5.0. These compositions may be
sterilized by conventional sterilization techniques, or may be
sterile filtered. The compositions may contain pharmaceutically
acceptable auxiliary substances as required to approximate
physiological conditions, such as pH buffering agents. Useful
buffers include for example, sodium acetate/acetic acid buffers. A
form of repository or "depot" slow release preparation may be used
so that therapeutically effective amounts of the preparation are
delivered into the bloodstream over many hours or days following
transdermal injection or delivery.
[0067] The desired isotonicity may be accomplished using sodium
chloride or other pharmaceutically acceptable agents such as
dextrose, boric acid, sodium tartrate, propylene glycol, polyols
(such as mannitol and sorbitol), or other inorganic or organic
solutes. Sodium chloride is preferred particularly for buffers
containing sodium ions.
[0068] The claimed compositions can also be formulated as
pharmaceutically acceptable salts (e.g., acid addition salts)
and/or complexes thereof. Pharmaceutically acceptable salts are
non-toxic salts at the concentration at which they are
administered. The preparation of such salts can facilitate the
pharmacological use by altering the physical-chemical
characteristics of the composition without preventing the
composition from exerting its physiological effect.
[0069] Examples of useful alterations in physical properties
include lowering the melting point to facilitate transmucosal
administration and increasing the solubility to facilitate the
administration of higher concentrations of the drug.
Pharmaceutically acceptable salts include acid addition salts such
as those containing sulfate, hydrochloride, phosphate, sulfamate,
acetate, citrate, lactate, tartrate, methanesulfonate,
ethanesulfonate, benzenesulfonate, p-toluenesulfonate,
cyclohexylsulfamate and quinate. Pharmaceutically acceptable salts
can be obtained from acids such as hydrochloric acid, sulfuric
acid, phosphoric acid, sulfamic acid, acetic acid, citric acid,
lactic acid, tartaric acid, malonic acid, methanesulfonic acid,
ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid,
cyclohexylsulfamic acid, and quinic acid. Such salts may be
prepared by, for example, reacting the free acid or base forms of
the product with one or more equivalents of the appropriate base or
acid in a solvent or medium in which the salt is insoluble, or in a
solvent such as water which is then removed in vacuo or by
freeze-drying or by exchanging the ions of an existing salt for
another ion on a suitable ion exchange resin.
[0070] Carriers or excipients can also be used to facilitate
administration of the compound. Examples of carriers and excipients
include calcium carbonate, calcium phosphate, various sugars such
as lactose, glucose, or sucrose, or types of starch, cellulose
derivatives, gelatin, vegetable oils, polyethylene glycols and
physiologically compatible solvents. The compositions or
pharmaceutical composition can be administered by different routes
including intravenously, intraperitoneal, subcutaneous, and
intramuscular, orally, topically, transmucosally, or by pulmonary
inhalation.
[0071] If desired, solutions of the above compositions may be
thickened with a thickening agent such as methyl cellulose. They
may be prepared in emulsified form, either water in oil or oil in
water. Any of a wide variety of pharmaceutically acceptable
emulsifying agents may be employed including, for example, acacia
powder, a non-ionic surfactant (such as a Tween), or an ionic
surfactant (such as alkali polyether alcohol sulfates or
sulfonates, e.g., a Triton).
[0072] Compositions useful in the invention are prepared by mixing
the ingredients following generally accepted procedures. For
example, the selected components may be simply mixed in a blender
or other standard device to produce a concentrated mixture which
may then be adjusted to the final concentration and viscosity by
the addition of water or thickening agent and possibly a buffer to
control pH or an additional solute to control tonicity.
[0073] For use by the physician, the compositions will be provided
in dosage unit form containing an amount of an exendin or exendin
agonist, for example, exendin-3, and/or exendin-4, with or without
another food intake-reducing, plasma glucose-lowering or plasma
lipid-lowering agent. Therapeutically effective amounts of an
exendin or exendin agonist for use in reducing food intake are
those that suppress appetite at a desired level. As will be
recognized by those in the field, an effective amount of
therapeutic agent will vary with many factors including the age and
weight of the patient, the patient's physical condition, the blood
sugar level and other factors.
[0074] The effective daily appetite-suppressing dose of the
compounds will typically be in the range of about 10 to 30 .mu.g to
about 5 mg/day, preferably about 10 to 30 .mu.g to about 2 mg/day
and more preferably about 10 to 100 .mu.g to about 1 mg/day, most
preferably about 30 .mu.g to about 500 .mu.g/day, for a 70 kg
patient, administered in a single or divided doses. The exact dose
to be administered is determined by the attending clinician and is
dependent upon where the particular compound lies within the above
quoted range, as well as upon the age, weight and condition of the
individual. Administration should begin whenever the suppression of
food intake, or weight lowering is desired, for example, at the
first sign of symptoms or shortly after diagnosis of obesity,
diabetes mellitus, or insulin-resistance syndrome. Administration
may be by injection, preferably subcutaneous or intramuscular.
Orally active compounds may be taken orally, however dosages should
be increased 5-10 fold.
[0075] The optimal formulation and mode of administration of
compounds of the present application to a patient depend on factors
known in the art such as the particular disease or disorder, the
desired effect, and the type of patient. While the compounds will
typically be used to treat human subjects they may also be used to
treat similar or identical diseases in other vertebrates such as
other primates, farm animals such as swine, cattle and poultry, and
sports animals and pets such as horses, dogs and cats.
[0076] To assist in understanding the present invention, the
following Examples are included. The experiments relating to this
invention should not, of course, be construed as specifically
limiting the invention and such variations of the invention, now
known or later developed, which would be within the purview of one
skilled in the art are considered to fall within the scope of the
invention as described herein and hereinafter claimed.
Example 1
Exendin Injections Reduced the Food Intake of Normal Mice
[0077] All mice (NIH:Swiss mice) were housed in a stable
environment of 22 (2).degree. C., 60 (10) % humidity and a 12:12
light:dark cycle; with lights on at 0600. Mice were housed in
groups of four in standard cages with ad libitum access to food
(Teklad: LM 485; Madison, Wis.) and water except as noted, for at
least two weeks before the experiments.
[0078] All experiments were conducted between the hours of 0700 and
0900. The mice were food deprived (food removed at 1600 hr from all
animals on day prior to experiment) and individually housed. All
mice received an intraperitoneal injection (5 .mu.l/kg) of either
saline or exendin-4 at doses of 0.1, 1.0, 10 and 100 .mu.g/kg and
were immediately presented with a pre-weighed food pellet (Teklad
LM 485). The food pellet was weighed at 30-minute, 1-hr, 2-hr and
6-hr intervals to determine the amount of food eaten.
[0079] FIG. 1 depicts cumulative food intake over periods of 0.5,
1, 2 and 6 hr in overnight-fasted normal NIH:Swiss mice following
ip injection of saline, 2 doses of GLP-1, or 4 doses of exendin-4.
At doses up to 100 .mu.g/kg, GLP-1 had no effect on food intake
measured over any period, a result consistent with that previously
reported (Bhaysar, S. P., et al., Soc. Neurosci. Abstr. 21:460
(188.8) (1995); and Turton, M. D., Nature, 379:69-72, (1996)).
[0080] In contrast, exendin-4 injections potently and
dose-dependently inhibited food intake. The ED.sub.50 for
inhibition of food intake over 30 min was 1 .mu.g/kg, which is a
level about as potent as amylin (ED.sub.50 3.6 .mu.g/kg) or the
prototypical peripheral satiety agent, CCK (ED.sub.50 0.97
.mu.g/kg) as measured in this preparation. However, in contrast to
the effects of amylin or CCK, which abate after 1-2 hours, the
inhibition of food intake with exendin-4 was still present after at
least 6 hours after injection.
Example 2
Exendin Reduced the Food Intake of Obese Mice
[0081] All mice (female ob/ob mice) were housed in a stable
environment of 22 (2).degree. C., 60 (10) % humidity and a 12:12
light:dark cycle; with lights on at 0600. Mice were housed in
groups of four in standard cages with ad libitum access to food
(Teklad: LM 485) and water except as noted, for at least two weeks
before the experiments.
[0082] All experiments were conducted between the hours of 0700 and
0900. The mice were food deprived (food removed at 1600 hr from all
animals on day prior to experiment) and individually housed. All
mice received an intraperitoneal injection (5 .mu.l/kg) of either
saline or exendin-4 at doses of 0.1, 1.0 and 10 .mu.g/kg (female
ob/ob mice) and were immediately presented with a pre-weighed food
pellet (Teklad LM 485). The food pellet was weighed at 30-minute,
1-hr, 2-hr and 6-hr intervals to determine the amount of food
eaten.
[0083] FIG. 2 depicts the effect of exendin-4 in the ob/ob mouse
model of obesity. The obese mice had a similar food intake-related
response to exendin as the normal mice. Moreover, the obese mice
were not hypersensitive to exendin, as has been observed with
amylin and leptin (Young, A. A., et al., Program and Abstracts,
10th International Congress of Endocrinology, Jun. 12-15, 1996 San
Francisco, pg 419 (P2-58)).
Example 3
Intracerebroventricular Injections of Exendin Inhibited Food Intake
in Rats
[0084] All rats (Harlan Sprague-Dawley) were housed in a stable
environment of 22 (2).degree. C., 60 (10) % humidity and a 12:12
light:dark cycle; with lights on at 0600. Rats were obtained from
Zivic Miller with an intracerebroventricular cannula (ICV cannula)
implanted (coordinates determined by actual weight of animals and
referenced to Paxinos, G. and Watson, C. "The Rat Brain in
stereotaxic coordinates," second edition. Academic Press) and were
individually housed in standard cages with ad libitum access to
food (Teklad: LM 485) and water for at least one week before the
experiments.
[0085] All injections were given between the hours of 1700 and
1800. The rats were habituated to the ICV injection procedure at
least once before the ICV administration of compound. All rats
received an ICV injection (2 .mu.l/30 seconds) of either saline or
exendin-4 at doses of 0.01, 0.03, 0.1, 0.3, and 1.0 .mu.g. All
animals were then presented with pre-weighed food (Teklad LM 485)
at 1800, when the lights were turned off. The amount of food left
was weighed at 2-hr, 12-hr and 24-hr intervals to determine the
amount of food eaten by each animal.
[0086] FIG. 3 depicts a dose-dependent inhibition of food intake in
rats that received doses greater than 0.1 .mu.g/rat. The ED.sub.50
was 0.1 .mu.g, exendin-4 is thus 100-fold more potent than
intracerebroventricular injections of GLP-1 as reported by Turton,
M. D., et al. (Nature 379:69-72 (1996)).
Example 4
Exendin Agonists Reduced the Food Intake in Mice
[0087] All mice (NIH:Swiss mice) were housed in a stable
environment of 22 (.+-.2).degree. C., 60 (.+-.10) % humidity and a
12:12 light:dark cycle; with lights on at 0600. Mice were housed in
groups of four in standard cages with ad libitum access to food
(Teklad: LM 485; Madison, Wis.) and water except as noted, for at
least two weeks before the experiments.
[0088] All experiments were conducted between the hours of 0700 and
0900. The mice were food deprived (food removed at 1600 hr from all
animals on day prior to experiment) and individually housed. All
mice received an intraperitoneal injection (5 .mu.l/kg) of either
saline or test compound at doses of 1, 10, and 100 .mu.g/kg and
immediately presented with a food pellet (Teklad LM 485). The food
pellet was weighed at 30-minute, 1-hr, 2-hr and 6-hr intervals to
determine the amount of food eaten.
[0089] FIG. 4 depicts the cumulative food intake over periods of
0.5, 1, 2 and 6 hr in overnight-fasted normal NIH:Swiss mice
following ip injection of saline or exendin-4 (1-30) ("Compound 1")
in doses of 1, 10 and 100 .mu.g/kg.
[0090] FIG. 5 depicts the cumulative food intake over periods of
0.5, 1, 2 and 6 hr in overnight-fasted normal NIH:Swiss mice
following ip injection of saline or exendin-4 (1-30) amide
("Compound 2") in doses of 1, 10 and 100 .mu.g/kg.
[0091] FIG. 6 depicts the cumulative food intake over periods of
0.5, 1, 2 and 6 hr in overnight-fasted normal NIH:Swiss mice
following ip injection of saline or exendin-4 (1-28) amide
("Compound 3") in doses of 1, 10 and 100 .mu.g/kg.
[0092] FIG. 7 depicts the cumulative food intake over periods of
0.5, 1, 2 and 6 hr in overnight-fasted normal NIH:Swiss mice
following ip injection of saline or .sup.14Leu,.sup.25Phe exendin-4
amide ("Compound 4") in doses of 1, 10 and 100 .mu.g/kg.
[0093] FIG. 8 depicts the cumulative food intake over periods of
0.5, 1, 2 and 6 hr in overnight-fasted normal NIH:Swiss mice
following ip injection of saline or .sup.14Leu,.sup.25Phe exendin-4
(1-28) amide ("Compound 5") in doses of 1, 10 and 100 .mu.g/kg.
[0094] FIG. 9 depicts the cumulative food intake over periods of
0.5, 1, 2 and 6 hr in overnight-fasted normal NIH:Swiss mice
following ip injection of saline or
.sup.14Leu,.sup.22Ala,.sup.25Phe exendin-4 (1-28) amide ("Compound
6") in doses of 1, 10 and 100 .mu.g/kg.
Example 5
Preparation of Amidated Peptide Having SEQ ID NO:9
[0095] The above-identified peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.). In general,
single-coupling cycles were used throughout the synthesis and Fast
Moc (HBTU activation) chemistry was employed. However, at some
positions coupling was less efficient than expected and double
couplings were required. In particular, residues Asp.sub.9,
Thr.sub.7 and Phe.sub.6 all required double coupling. Deprotection
(Fmoc group removal) of the growing peptide chain using piperidine
was not always efficient. Double deprotection was required at
positions Arg.sub.20, Val.sub.19 and Leu.sub.14. Final deprotection
of the completed peptide resin was achieved using a mixture of
triethylsilane (0.2 mL), ethanedithiol (0.2 mL), anisole (0.2 mL),
water (0.2 mL) and trifluoroacetic acid (15 mL) according to
standard methods (Introduction to Cleavage Techniques, Applied
Biosystems, Inc.) The peptide was precipitated in ether/water (50
mL) and centrifuged. The precipitate was reconstituted in glacial
acetic acid and lyophilized. The lyophilized peptide was dissolved
in water). Crude purity was about 55%.
[0096] Used in purification steps and analysis were Solvent A (0.1%
TFA in water) and Solvent B (0.1% TFA in ACN).
[0097] The solution containing peptide was applied to a preparative
C-18 column and purified (10% to 40% Solvent B in Solvent A over 40
minutes). Purity of fractions was determined isocratically using a
C-18 analytical column. Pure fractions were pooled furnishing the
above-identified peptide. Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
gave product peptide having an observed retention time of 14.5
minutes. Electrospray Mass Spectrometry (M): calculated 4131.7.
found 4129.3.
Example 6
Preparation of Peptide Having SEQ ID NO:10
[0098] The above-identified peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 5.
Used in analysis were Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 25% to 75% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 21.5 minutes.
Electrospray Mass Spectrometry (M): calculated 4168.6. found
4171.2.
Example 7
Preparation of Peptide Having SEQ ID NO:11
[0099] The above-identified peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 5.
Used in analysis were Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 17.9 minutes.
Electrospray Mass Spectrometry (M): calculated 4147.6. found
4150.2.
Example 8
Preparation of Peptide Having SEQ ID NO:12
[0100] The above-identified peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 5.
Used in analysis were Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 35% to 65% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 19.7 minutes.
Electrospray Mass Spectrometry (M): calculated 4212.6. found
4213.2.
Example 9
Preparation of Peptide Having SEQ ID NO:13
[0101] The above-identified peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 5.
Used in analysis were Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 50% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 16.3 minutes.
Electrospray Mass Spectrometry (M): calculated 4262.7. found
4262.4.
Example 10
Preparation of Peptide Having SEQ ID NO:14
[0102] The above-identified peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 5.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 4172.6
Example 11
Preparation of Peptide Having SEQ ID NO:15
[0103] The above-identified peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 5.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 4224.7.
Example 12
Preparation of Peptide Having SEQ ID NO:16
[0104] The above-identified peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 5.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 4172.6
Example 13
Preparation of Peptide Having SEQ ID NO:17
[0105] The above-identified peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 5.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 4186.6
Example 14
Preparation of Peptide Having SEQ ID NO:18
[0106] The above-identified peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 5.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 4200.7
Example 15
Preparation of Peptide Having SEQ ID NO:19
[0107] The above-identified peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 5.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 4200.7
Example 16
Preparation of Peptide Having SEQ ID NO:20
[0108] The above-identified peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 5.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 4202.7.
Example 17
Preparation of Peptide Having SEQ ID NO:21
[0109] The above-identified peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 5.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 4145.6.
Example 18
Preparation of Peptide Having SEQ ID NO:22
[0110] The above-identified peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 5.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 4184.6.
Example 19
Preparation of Peptide Having SEQ ID NO:23
[0111] The above-identified peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 5.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 4145.6.
Example 20
Preparation of Peptide Having SEQ ID NO:24
[0112] The above-identified peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 5.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 4224.7.
Example 21
Preparation of Peptide Having SEQ ID NO:25
[0113] The above-identified peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 5.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 4172.6.
Example 22
Preparation of Peptide Having SEQ ID NO:26
[0114] The above-identified peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 5.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 4115.5.
Example 23
Preparation of Peptide Having SEQ ID NO:27
[0115] The above-identified peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 5.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 4188.6.
Example 24
Preparation of Peptide Having SEQ ID NO:28
[0116] The above-identified peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 5.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 4131.6.
Example 25
Preparation of Peptide Having SEQ ID NO:29
[0117] The above-identified peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 5.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 4172.6.
Example 26
Preparation of Peptide Having SEQ ID NO:30
[0118] The above-identified peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 5.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 4145.6.
Example 27
Preparation of Peptide Having SEQ ID NO:31
[0119] The above-identified peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 5.
Additional double couplings are required at the thioproline
positions 38, 37, 36 and 31. Used in analysis are Solvent A (0.1%
TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC
(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the
lyophilized peptide is then carried out to determine the retention
time of the product peptide. Electrospray Mass Spectrometry (M):
calculated 4266.8.
Example 28
Preparation of Peptide Having SEQ ID NO:32
[0120] The above-identified peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 5.
Additional double couplings are required at the thioproline
positions 38, 37 and 36. Used in analysis are Solvent A (0.1% TFA
in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC
(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the
lyophilized peptide is then carried out to determine the retention
time of the product peptide. Electrospray Mass Spectrometry (M):
calculated 4246.8.
Example 29
Preparation of Peptide Having SEQ ID NO:33
[0121] The above-identified peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 5.
Additional double couplings are required at the homoproline
positions 38, 37, 36 and 31. Used in analysis are Solvent A (0.1%
TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC
(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the
lyophilized peptide is then carried out to determine the retention
time of the product peptide. Electrospray Mass Spectrometry (M):
calculated 4250.8.
Example 30
Preparation of Peptide Having SEQ ID NO:34
[0122] The above-identified peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 5.
Additional double couplings are required at the homoproline
positions 38, 37, and 36. Used in analysis are Solvent A (0.1% TFA
in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC
(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the
lyophilized peptide is then carried out to determine the retention
time of the product peptide. Electrospray Mass Spectrometry (M):
calculated 4234.8.
Example 31
Preparation of Peptide Having SEQ ID NO:35
[0123] The above-identified peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 5.
Additional double couplings are required at the thioproline
positions 38, 37, 36 and 31. Used in analysis are Solvent A (0.1%
TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC
(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the
lyophilized peptide is then carried out to determine the retention
time of the product peptide. Electrospray Mass Spectrometry (M):
calculated 4209.8.
Example 32
Preparation of Peptide Having SEQ ID NO:36
[0124] The above-identified peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 5.
Additional double couplings are required at the homoproline
positions 38, 37, 36 and 31. Used in analysis are Solvent A (0.1%
TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC
(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the
lyophilized peptide is then carried out to determine the retention
time of the product peptide. Electrospray Mass Spectrometry (M):
calculated 4193.7.
Example 33
Preparation of Peptide Having SEQ ID NO:37
[0125] The above-identified peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 5.
Additional double couplings are required at the N-methylalanine
positions 38, 37, 36 and 31. Used in analysis are Solvent A (0.1%
TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC
(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the
lyophilized peptide is then carried out to determine the retention
time of the product peptide. Electrospray Mass Spectrometry (M):
calculated 3858.2.
Example 34
Preparation of Peptide Having SEQ ID NO:38
[0126] The above-identified peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 5.
Additional double couplings are required at the N-methylalanine
positions 38, 37 and 36. Used in analysis are Solvent A (0.1% TFA
in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC
(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the
lyophilized peptide is then carried out to determine the retention
time of the product peptide. Electrospray Mass Spectrometry (M):
calculated 3940.3.
Example 35
Preparation of Peptide Having SEQ ID NO:39
[0127] The above-identified peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 5.
Additional double couplings are required at the N-methylalanine
positions 38, 37, 36 and 31. Used in analysis are Solvent A (0.1%
TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC
(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the
lyophilized peptide is then carried out to determine the retention
time of the product peptide. Electrospray Mass Spectrometry (M):
calculated 3801.1.
Example 36
Preparation of C-Terminal Carboxylic Acid Peptides Corresponding to
the Above C-Terminal Amide Sequences
[0128] The above peptides of Examples 5 to 35 are assembled on the
so called Wang resin (p-alkoxybenzylalacohol resin (Bachem, 0.54
mmole/g)) using Fmoc-protected amino acids (Applied Biosystems,
Inc.), cleaved from the resin, deprotected and purified in a
similar way to Example 5. Used in analysis are Solvent A (0.1% TFA
in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC
(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the
lyophilized peptide is then carried out to determine the retention
time of the product peptide. Electrospray Mass Spectrometry
provides an experimentally determined (M).
Example 37
Preparation of Peptide Having SEQ ID NO:7
TABLE-US-00004 [0129] (SEQ ID NO: 7) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn Gly Gly-NH.sub.2
[0130] The above amidated peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.). In general,
single-coupling cycles were used throughout the synthesis and Fast
Moc (HBTU activation) chemistry was employed. Deprotection (Fmoc
group removal) of the growing peptide chain was achieved using
piperidine. Final deprotection of the completed peptide resin was
achieved using a mixture of triethylsilane (0.2 mL), ethanedithiol
(0.2 mL), anisole (0.2 mL), water (0.2 mL) and trifluoroacetic acid
(15 mL) according to standard methods (Introduction to Cleavage
Techniques, Applied Biosystems, Inc.) The peptide was precipitated
in ether/water (50 mL) and centrifuged. The precipitate was
reconstituted in glacial acetic acid and lyophilized. The
lyophilized peptide was dissolved in water). Crude purity was about
75%.
[0131] Used in purification steps and analysis were Solvent A (0.1%
TFA in water) and Solvent B (0.1% TFA in ACN). The solution
containing peptide was applied to a preparative C-18 column and
purified (10% to 40% Solvent B in Solvent A over 40 minutes).
Purity of fractions was determined isocratically using a C-18
analytical column. Pure fractions were pooled furnishing the
above-identified peptide. Analytical RP-HPLC (gradient 30% to 50%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
gave product peptide having an observed retention time of 18.9
minutes. Electrospray Mass Spectrometry (M): calculated 3408.0.
found 3408.9.
Example 38
Preparation of Peptide Having SEQ ID NO:40
TABLE-US-00005 [0132] (SEQ ID NO: 40) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn-NH2
[0133] The above amidated peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis were Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 40% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 17.9 minutes.
Electrospray Mass Spectrometry (M): calculated 3294.7. found
3294.8.
Example 39
Preparation of Peptide Having SEQ ID NO:41
TABLE-US-00006 [0134] (SEQ ID NO: 41) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn-NH2
[0135] The above-identified amidated peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis were Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 29% to 36% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 20.7 minutes.
Electrospray Mass Spectrometry (M): calculated 3237.6. found
3240.
Example 40
Preparation of Peptide Having SEQ ID NO:42
TABLE-US-00007 [0136] (SEQ ID NO: 42) His Ala Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn-NH2
[0137] The above amidated peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis were Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 36% to 46% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 15.2 minutes.
Electrospray Mass Spectrometry (M): calculated 3251.6. found
3251.5.
Example 41
Preparation of Peptide Having SEQ ID NO:43
TABLE-US-00008 [0138] (SEQ ID NO: 43) His Gly Glu Gly Ala Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn-NH2
[0139] The above amidated peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis were Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 36% to 46% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 13.1 minutes.
Electrospray Mass Spectrometry (M): calculated 3207.6. found
3208.3.
Example 42
Preparation of Peptide Having SEQ ID NO:44
TABLE-US-00009 [0140] (SEQ ID NO: 44) His Gly Glu Gly Thr Ala Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn-NH2
[0141] The above amidated peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis were Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 35% to 45% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 12.8 minutes.
Electrospray Mass Spectrometry (M): calculated 3161.5. found
3163.
Example 43
Preparation of Peptide Having SEQ ID NO:45
TABLE-US-00010 [0142] (SEQ ID NO: 45) His Gly Glu Gly Thr Phe Thr
Ala Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn-NH2
[0143] The above-identified amidated peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis were Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 36% to 46% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 15.2 minutes.
Electrospray Mass Spectrometry (M): calculated 3221.6. found
3222.7.
Example 44
Preparation of Peptide Having SEQ ID NO:46
TABLE-US-00011 [0144] (SEQ ID NO: 46) His Gly Glu Gly Thr Phe Thr
Ser Asp Ala Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn-NH2
[0145] The above-identified amidated peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis were Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 34% to 44% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 14.3 minutes.
Electrospray Mass Spectrometry (M): calculated 3195.5. found
3199.4.
Example 45
Preparation of Peptide Having SEQ ID NO:47
TABLE-US-00012 [0146] (SEQ ID NO: 47) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ala Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn-NH2
[0147] The above-identified amidated peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis were Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 38% to 48% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 15.7 minutes.
Electrospray Mass Spectrometry (M): calculated 3221.6. found
3221.6.
Example 46
Preparation of Peptide Having SEQ ID NO:48
TABLE-US-00013 [0148] (SEQ ID NO: 48) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Ala Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn-NH2
[0149] The above-identified amidated peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis were Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 38% to 48% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 18.1 minutes.
Electrospray Mass Spectrometry (M): calculated 3180.5. found
3180.9.
Example 47
Preparation of Peptide Having SEQ ID NO:49
TABLE-US-00014 [0150] (SEQ ID NO: 49) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Ala Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn-NH2
[0151] The above-identified amidated peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Compound 1.
Used in analysis were Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 36% to 46% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 17.0 minutes.
Electrospray Mass Spectrometry (M): calculated 3180.6. found
3182.8.
Example 48
Preparation of Peptide Having SEQ ID NO:50
TABLE-US-00015 [0152] (SEQ ID NO: 50) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Ala Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn-NH2
[0153] The above-identified amidated peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis were Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 32% to 42% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 14.9 minutes.
Electrospray Mass Spectrometry (M): calculated 3195.5. found
3195.9.
Example 49
Preparation of Peptide Having SEQ ID NO:51
TABLE-US-00016 [0154] (SEQ ID NO: 51) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Ala Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn-NH2
[0155] The above-identified amidated peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis were Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 37% to 47% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 17.9 minutes.
Electrospray Mass Spectrometry (M): calculated 3179.6. found
3179.0.
Example 50
Preparation of Peptide Having SEQ ID NO:52
TABLE-US-00017 [0156] (SEQ ID NO: 52) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Ala Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn-NH2
[0157] The above-identified amidated peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis were Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 37% to 47% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 14.3 minutes.
Electrospray Mass Spectrometry (M): calculated 3179.6. found
3180.0.
Example 51
Preparation of Peptide Having SEQ ID NO:53
TABLE-US-00018 [0158] (SEQ ID NO: 53) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Ala Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn-NH2
[0159] The above-identified peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis were Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 37% to 47% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 13.7 minutes.
Electrospray Mass Spectrometry (M): calculated 3179.6. found
3179.0.
Example 52
Preparation of Peptide Having SEQ ID NO:54
TABLE-US-00019 [0160] (SEQ ID NO: 54) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Ala Arg Leu Phe Ile Glu
Phe Leu Lys Asn-NH2
[0161] The above-identified amidated peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis were Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 35% to 45% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 14.0 minutes.
Electrospray Mass Spectrometry (M): calculated 3209.6. found
3212.8.
Example 53
Preparation of Peptide Having SEQ ID NO:55
TABLE-US-00020 [0162] (SEQ ID NO: 55) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Ala Leu Phe Ile Glu
Phe Leu Lys Asn-NH2
[0163] The above-identified amidated peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis were Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 38% to 48% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 14.3 minutes.
Electrospray Mass Spectrometry (M): calculated 3152.5. found
3153.5.
Example 54
Preparation of Peptide Having SEQ ID NO:56
TABLE-US-00021 [0164] (SEQ ID NO: 56) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Ala Phe Ile Glu
Phe Leu Lys Asn-NH2
[0165] The above-identified amidated peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis were Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 35% to 45% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 12.1 minutes.
Electrospray Mass Spectrometry (M): calculated 3195.5. found
3197.7.
Example 55
Preparation of Peptide Having SEQ ID NO:57
TABLE-US-00022 [0166] (SEQ ID NO: 57) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Ala
Phe Leu Lys Asn-NH2
[0167] The above-identified amidated peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis were Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 38% to 48% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 10.9 minutes.
Electrospray Mass Spectrometry (M): calculated 3179.6. found
3180.5.
Example 56
Preparation of Peptide Having SEQ ID NO:58
TABLE-US-00023 [0168] (SEQ ID NO: 58) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Ala Leu Lys Asn-NH2
[0169] The above-identified amidated peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis were Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 32% to 42% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 17.5 minutes.
Electrospray Mass Spectrometry (M): calculated 3161.5. found
3163.0.
Example 57
Preparation of Peptide Having SEQ ID NO:59
TABLE-US-00024 [0170] (SEQ ID NO: 59) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Ala Lys Asn-NH2
[0171] The above-identified amidated peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis were Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 32% to 42% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 19.5 minutes.
Electrospray Mass Spectrometry (M): calculated 3195.5. found
3199.
Example 58
Preparation of Peptide Having SEQ ID NO:60
TABLE-US-00025 [0172] (SEQ ID NO: 60) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Ala Asn-NH2
[0173] The above-identified amidated peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis were Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 38% to 48% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 14.5 minutes.
Electrospray Mass Spectrometry (M): calculated 3180.5. found
3183.7.
Example 59
Preparation of Peptide Having SEQ ID NO:61
TABLE-US-00026 [0174] (SEQ ID NO: 61) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Ala-NH2
[0175] The above-identified amidated peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis were Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 34% to 44% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide gave
product peptide having an observed retention time of 22.8 minutes.
Electrospray Mass Spectrometry (M): calculated 3194.6. found
3197.6.
Example 60
Preparation of Peptide Having SEQ ID NO:62
TABLE-US-00027 [0176] (SEQ ID NO: 62) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro-NH2
[0177] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 4099.6.
Example 61
Preparation of Peptide Having SEQ ID NO:63
TABLE-US-00028 [0178] (SEQ ID NO: 63) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro-NH2
[0179] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 4042.5.
Example 62
Preparation of Peptide Having SEQ ID NO:64
TABLE-US-00029 [0180] (SEQ ID NO: 64) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro-NH2
[0181] The above-identified peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 4002.4
Example 63
Preparation of Peptide Having SEQ ID NO:65
TABLE-US-00030 [0182] (SEQ ID NO: 65) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro-NH2
[0183] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 3945.4.
Example 64
Preparation of Peptide Having SEQ ID NO:66
TABLE-US-00031 [0184] (SEQ ID NO: 66) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro-NH2
[0185] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 3905.3.
Example 65
Preparation of Peptide Having SEQ ID NO:67
TABLE-US-00032 [0186] (SEQ ID NO: 67) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro-NH2
[0187] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 3848.2.
Example 66
Preparation of Peptide Having SEQ ID NO:68
TABLE-US-00033 [0188] (SEQ ID NO: 68) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala-NH2
[0189] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 3808.2.
Example 67
Preparation of Peptide Having SEQ ID NO:69
TABLE-US-00034 [0190] (SEQ ID NO: 69) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala-NH2
[0191] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 3751.1.
Example 68
Preparation of Peptide Having SEQ ID NO:70
TABLE-US-00035 [0192] (SEQ ID NO: 70) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly-NH2
[0193] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 3737.1.
Example 69
Preparation of Peptide Having SEQ ID NO:71
TABLE-US-00036 [0194] (SEQ ID NO: 71) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn Gly Gly Pro Ser Ser Gly-NH2
[0195] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 3680.1.
Example 70
Preparation of Peptide Having SEQ ID NO:72
TABLE-US-00037 [0196] (SEQ ID NO: 72) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn Gly Gly Pro Ser Ser-NH2
[0197] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 3680.1
Example 71
Preparation of Peptide Having SEQ ID NO:73
TABLE-US-00038 [0198] (SEQ ID NO: 73) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn Gly Gly Pro Ser Ser-NH2
[0199] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 3623.0.
Example 72
Preparation of Peptide Having SEQ ID NO:74
TABLE-US-00039 [0200] (SEQ ID NO: 74) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn Gly Gly Pro Ser-NH2
[0201] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 3593.0
Example 73
Preparation of Peptide Having SEQ ID NO:75
TABLE-US-00040 [0202] (SEQ ID NO: 75) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn Gly Gly Pro Ser-NH2
[0203] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 3535.9
Example 74
Preparation of Peptide Having SEQ ID NO:76
TABLE-US-00041 [0204] (SEQ ID NO: 76) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn Gly Gly Pro-NH2
[0205] The above-identified peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 3505.9.
Example 75
Preparation of Peptide Having SEQ ID NO:77
TABLE-US-00042 [0206] (SEQ ID NO: 77) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn Gly Gly Pro-NH2
[0207] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 3448.8.
Example 76
Preparation of Peptide Having SEQ ID NO:78
TABLE-US-00043 [0208] (SEQ ID NO: 78) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn Gly Gly-NH2
[0209] The above-identified peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 3351.7.
Example 77
Preparation of Peptide Having SEQ ID NO:79
TABLE-US-00044 [0210] (SEQ ID NO: 79) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn Gly-NH.sub.2
[0211] The above-identified peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 3351.8.
Example 78
Preparation of Peptide Having SEQ ID NO:80
TABLE-US-00045 [0212] (SEQ ID NO: 80) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn Gly-NH2
[0213] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 3294.7.
Example 79
Preparation of Peptide Having SEQ ID NO:81
TABLE-US-00046 [0214] (SEQ ID NO: 81) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn Gly Gly tPro Ser Ser Gly Ala tPro tPro tPro-NH2
[0215] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Double couplings are required at residues 37, 36 and 31. Used in
analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 4197.1.
Example 80
Preparation of Peptide Having SEQ ID NO:82
TABLE-US-00047 [0216] (SEQ ID NO: 82) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala tPro tPro tPro-NH2
[0217] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Double couplings are required at residues 37, 36 and 31. Used in
analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 4179.1.
Example 81
Preparation of Peptide Having SEQ ID NO:83
TABLE-US-00048 [0218] (SEQ ID NO: 83) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn Gly Gly NMeala Ser Ser Gly Ala Pro Pro-NH2
[0219] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Double couplings are required at residues 36 and 31. Used in
analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 3948.3.
Example 82
Preparation of Peptide Having SEQ ID NO:84
TABLE-US-00049 [0220] (SEQ ID NO: 84) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn Gly Gly NMeala Ser Ser Gly Ala NMeala
Nmeala-NH2
[0221] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Double couplings are required at residues 36 and 31. Used in
analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 3840.1.
Example 83
Preparation of Peptide Having SEQ ID NO:85
TABLE-US-00050 [0222] (SEQ ID NO: 85) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn Gly Gly hPro Ser Ser Gly Ala hPro hPro-NH2
[0223] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Double couplings are required at residues 36 and 31. Used in
analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 4050.1.
Example 84
Preparation of Peptide Having SEQ ID NO:86
TABLE-US-00051 [0224] (SEQ ID NO: 86) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn Gly Gly hPro Ser Ser Gly Ala hPro-NH2
[0225] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
A double coupling is required at residue 31. Used in analysis are
Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over
30 minutes) of the lyophilized peptide is then carried out to
determine the retention time of the product peptide. Electrospray
Mass Spectrometry (M): calculated 3937.1
Example 85
Preparation of Peptide Having SEQ ID NO:87
TABLE-US-00052 [0226] (SEQ ID NO: 87 Arg Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala-NH2
[0227] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 3827.2.
Example 86
Preparation of Peptide Having SEQ ID NO:88
TABLE-US-00053 [0228] (SEQ ID NO: 88) His Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn Gly Gly-NH2
[0229] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 3394.8.
Example 87
Preparation of Peptide Having SEQ ID NO:89
TABLE-US-00054 [0230] (SEQ ID NO: 89) His Gly Glu Gly Thr
Naphthylala Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg
Leu Phe Ile Glu Phe Leu Lys Asn-NH2
[0231] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 3289.5.
Example 88
Preparation of Peptide Having SEQ ID NO:90
TABLE-US-00055 [0232] (SEQ ID NO: 90) His Gly Glu Gly Thr Phe Ser
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn-NH2
[0233] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 3280.7.
Example 89
Preparation of Peptide Having SEQ ID NO:91
TABLE-US-00056 [0234] (SEQ ID NO: 91) His Gly Glu Gly Thr Phe Ser
Thr Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn-NH2
[0235] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 3294.7.
Example 90
Preparation of Peptide Having SEQ ID NO:92
TABLE-US-00057 [0236] (SEQ ID NO: 92) His Gly Glu Gly Thr Phe Thr
Ser Glu Leu Ser Lys Gln Met Ala Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn-NH2
[0237] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 3250.7.
Example 91
Preparation of Peptide Having SEQ ID NO:93
TABLE-US-00058 [0238] (SEQ ID NO: 93) His Gly Glu Gly Thr Phe Thr
Ser Asp pentylgly Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn-NH2
[0239] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 3253.5.
Example 92
Preparation of Peptide Having SEQ ID NO:94
TABLE-US-00059 [0240] (SEQ ID NO: 94) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Naphthylala
Ile Glu Phe Leu Lys Asn-NH2
[0241] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 3289.5.
Example 93
Preparation of Peptide Having SEQ ID NO:95
TABLE-US-00060 [0242] (SEQ ID NO: 95) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe
tButylgly Glu Trp Leu Lys Asn-NH2
[0243] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 3183.4.
Example 94
Preparation of Peptide Having SEQ ID NO:96
TABLE-US-00061 [0244] (SEQ ID NO: 96) His Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Asp
Phe Leu Lys Asn-NH2
[0245] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 3237.6.
Example 95
Preparation of Peptide Having SEQ ID NO:97
TABLE-US-00062 [0246] (SEQ ID NO: 97) His Gly Glu Gly Thr Phe Thr
Ser Asp Ala Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn Gly Gly Pro Ser Ser-NH2
[0247] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 3637.9.
Example 96
Preparation of Peptide Having SEQ ID NO:98
TABLE-US-00063 [0248] (SEQ ID NO: 98) His Gly Glu Gly Thr Phe Thr
Ser Asp Ala Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn Gly-NH2
[0249] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 3309.7.
Example 97
Preparation of Peptide Having SEQ ID NO:99
TABLE-US-00064 [0250] (SEQ ID NO: 99) His Gly Glu Gly Thr Phe Thr
Ser Asp Ala Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn Gly Gly hPro Ser Ser Gly Ala hPro hPro-NH2
[0251] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Ecample 37.
Double couplings are required at residues 36 and 31. Used in
analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 3711.1.
Example 98
Preparation of C-Terminal Carboxylic Acid Peptides Corresponding to
the Above C-Terminal Amide Sequences for SEQ ID NOs:7, 40-61,
68-75, 78-80 and 87-96
[0252] Peptides having the sequences of SEQ ID NOs:7, 40-61, 68-75,
78-80 and 87-96 are assembled on the so called Wang resin
(p-alkoxybenzylalacohol resin (Bachem, 0.54 mmole/g)) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry provides an experimentally
determined (M).
Example 99
Preparation of C-Terminal Carboxylic Acid Peptides Corresponding to
the Above C-Terminal Amide Sequences for SEQ ID NOs:62-67, 76, 77
and 81-86
[0253] Peptides having the sequences of SEQ ID NOs:62-67, 76, 77
and 81-86 are assembled on the 2-chlorotritylchloride resin
(200-400 mesh), 2% DVB (Novabiochem, 0.4-1.0 mmole/g)) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example 37.
Used in analysis are Solvent A (0.1% TFA in water) and Solvent B
(0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent
B in Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry provides an experimentally
determined (M).
Example 100
Preparation of Peptide Having SEQ ID NO:100
TABLE-US-00065 [0254] (SEQ ID NO: 100) Ala Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn-NH2
[0255] The above amidated peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.). In general,
single-coupling cycles were used throughout the synthesis and Fast
Moc (HBTU activation) chemistry was employed. Deprotection (Fmoc
group removal) of the growing peptide chain was achieved using
piperidine. Final deprotection of the completed peptide resin was
achieved using a mixture of triethylsilane (0.2 mL), ethanedithiol
(0.2 mL), anisole (0.2 mL), water (0.2 mL) and trifluoroacetic acid
(15 mL) according to standard methods (Introduction to Cleavage
Techniques, Applied Biosystems, Inc.) The peptide was precipitated
in ether/water (50 mL) and centrifuged. The precipitate was
reconstituted in glacial acetic acid and lyophilized. The
lyophilized peptide was dissolved in water). Crude purity was about
75%.
[0256] Used in purification steps and analysis were Solvent A (0.1%
TFA in water) and Solvent B (0.1% TFA in ACN). The solution
containing peptide was applied to a preparative C-18 column and
purified (10% to 40% Solvent B in Solvent A over 40 minutes).
Purity of fractions was determined isocratically using a C-18
analytical column. Pure fractions were pooled furnishing the
above-identified peptide. Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
gave product peptide having an observed retention time of 19.2
minutes. Electrospray Mass Spectrometry (M): calculated 3171.6.
found 3172.
Example 101
Preparation of Peptide Having SEQ ID NO:101
TABLE-US-00066 [0257] (SEQ ID NO: 101) His Gly Ala Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn-NH2
[0258] The above amidated peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis were Solvent A (0.1% TFA in water) and
Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 36% to
46% Solvent B in Solvent A over 30 minutes) of the lyophilized
peptide gave product peptide having an observed retention time of
14.9 minutes. Electrospray Mass Spectrometry (M): calculated
3179.6. found 3180.
Example 102
Preparation of Peptide Having SEQ ID NO:102
TABLE-US-00067 [0259] (SEQ ID NO: 102) His Gly Glu Ala Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn-NH2
[0260] The above amidated peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis were Solvent A (0.1% TFA in water) and
Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 37% to
47% Solvent B in Solvent A over 30 minutes) of the lyophilized
peptide gave product peptide having an observed retention time of
12.2 minutes. Electrospray Mass Spectrometry (M): calculated
3251.6. found 3253.3.
Example 103
Preparation of Peptide Having SEQ ID NO:103
TABLE-US-00068 [0261] (SEQ ID NO: 103) His Gly Glu Gly Thr Phe Thr
Ser Ala Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn-NH2
[0262] The above amidated peptide was assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis were Solvent A (0.1% TFA in water) and
Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 35% to
45% Solvent B in Solvent A over 30 minutes) of the lyophilized
peptide gave product peptide having an observed retention time of
16.3 minutes. Electrospray Mass Spectrometry (M): calculated
3193.6. found 3197.
Example 104
Preparation of Peptide Having SEQ ID NO:104
TABLE-US-00069 [0263] (SEQ ID NO: 104) Ala Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn-NH2
[0264] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3228.6.
Example 105
Preparation of Peptide Having SEQ ID NO:105
TABLE-US-00070 [0265] (SEQ ID NO: 105) His Gly Ala Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn-NH2
[0266] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3234.7.
Example 106
Preparation of Peptide Having SEQ ID NO:106
TABLE-US-00071 [0267] (SEQ ID NO: 106) His Gly Glu Ala Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn-NH2
[0268] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3308.7.
Example 107
Preparation of Peptide Having SEQ ID NO:107
TABLE-US-00072 [0269] (SEQ ID NO: 107) His Gly Glu Gly Thr Phe Thr
Ser Ala Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn-NH2
[0270] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3250.7
Example 108
Preparation of Peptide Having SEQ ID NO:108
TABLE-US-00073 [0271] (SEQ ID NO: 108) His Gly Glu Gly Thr Phe Thr
Ser Asp Ala Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn-NH2
[0272] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3252.6.
Example 109
Preparation of Peptide Having SEQ ID NO:109
TABLE-US-00074 [0273] (SEQ ID NO: 109) Ala Ala Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn-NH2
[0274] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3200.6.
Example 110
Preparation of Peptide Having SEQ ID NO:110
TABLE-US-00075 [0275] (SEQ ID NO: 110) Ala Ala Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn-NH2
[0276] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3143.5.
Example 111
Preparation of Peptide Having SEQ ID NO:111
TABLE-US-00076 [0277] (SEQ ID NO: 111) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn-NH2
[0278] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3214.6.
Example 112
Preparation of Peptide Having SEQ ID NO:112
TABLE-US-00077 [0279] (SEQ ID NO: 112) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn-NH2
[0280] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3157.5.
Example 113
Preparation of Peptide Having SEQ ID NO:113
TABLE-US-00078 [0281] (SEQ ID NO: 113) Ala Gly Asp Gly Ala Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn-NH2
[0282] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3184.6.
Example 114
Preparation of Peptide Having SEQ ID NO:114
TABLE-US-00079 [0283] (SEQ ID NO: 114) Ala Gly Asp Gly Ala Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn-NH2
[0284] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3127.5.
Example 115
Preparation of Peptide Having SEQ ID NO:115
TABLE-US-00080 [0285] (SEQ ID NO: 115) Ala Gly Asp Gly Thr
NaphthylAla Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg
Leu Phe Ile Glu Trp Leu Lys Asn-NH2
[0286] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3266.4.
Example 116
Preparation of Peptide Having SEQ ID NO:116
TABLE-US-00081 [0287] (SEQ ID NO: 116) Ala Gly Asp Gly Thr
Naphthylala Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg
Leu Phe Ile Glu Phe Leu Lys Asn-NH2
[0288] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3209.4.
Example 117
Preparation of Peptide Having SEQ ID NO:117
TABLE-US-00082 [0289] (SEQ ID NO: 117) Ala Gly Asp Gly Thr Phe Ser
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn-NH2
[0290] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3200.6.
Example 118
Preparation of Peptide Having SEQ ID NO:118
TABLE-US-00083 [0291] (SEQ ID NO: 118) Ala Gly Asp Gly Thr Phe Ser
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn-NH2
[0292] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3143.5.
Example 119
Preparation of Peptide Having SEQ ID NO:119
TABLE-US-00084 [0293] (SEQ ID NO: 119) Ala Gly Asp Gly Thr Phe Thr
Ala Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn-NH2
[0294] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3198.6.
Example 120
Preparation of Peptide Having SEQ ID NO:120
TABLE-US-00085 [0295] (SEQ ID NO: 120) Ala Gly Asp Gly Thr Phe Thr
Ala Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn-NH2
[0296] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3141.5.
Example 121
Preparation of Peptide Having SEQ ID NO:121
TABLE-US-00086 [0297] (SEQ ID NO: 121) Ala Gly Asp Gly Thr Phe Thr
Ser Ala Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn-NH2
[0298] The above-identified peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3170.6.
Example 122
Preparation of Peptide Having SEQ ID NO:122
TABLE-US-00087 [0299] (SEQ ID NO: 122) Ala Gly Asp Gly Thr Phe Thr
Ser Ala Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn-NH2
[0300] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3113.5.
Example 123
Preparation of Peptide Having SEQ ID NO:123
TABLE-US-00088 [0301] (SEQ ID NO: 123) Ala Gly Asp Gly Thr Phe Thr
Ser Glu Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn-NH2
[0302] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3228.6.
Example 124
Preparation of Peptide Having SEQ ID NO:124
TABLE-US-00089 [0303] (SEQ ID NO: 124) Ala Gly Asp Gly Thr Phe Thr
Ser Glu Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn-NH2
[0304] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3171.6.
Example 125
Preparation of Peptide Having SEQ ID NO:125
TABLE-US-00090 [0305] (SEQ ID NO: 125) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Ala Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn-NH2
[0306] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3172.5.
Example 126
Preparation of Peptide Having SEQ ID NO:126
TABLE-US-00091 [0307] (SEQ ID NO: 126) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Ala Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn-NH2
[0308] The above-identified amidated peptiden is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3115.4.
Example 127
Preparation of Peptide Having SEQ ID NO:127
TABLE-US-00092 [0309] (SEQ ID NO: 127) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Pentylgly Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe
Ile Glu Trp Leu Lys Asn-NH2
[0310] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3230.4.
Example 128
Preparation of Peptide Having SEQ ID NO:128
TABLE-US-00093 [0311] (SEQ ID NO: 128) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Pentylgly Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn-NH2
[0312] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3198.6.
Example 129
Preparation of Peptide Having SEQ ID NO:129
TABLE-US-00094 [0313] (SEQ ID NO: 129) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ala Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn-NH2
[0314] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3141.5.
Example 130
Preparation of Peptide Having SEQ ID NO:130
TABLE-US-00095 [0315] (SEQ ID NO: 130) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ala Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn-NH2
[0316] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3157.5.
Example 131
Preparation of Peptide Having SEQ ID NO:131
TABLE-US-00096 [0317] (SEQ ID NO: 131) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Ala Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn-NH2
[0318] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3100.4.
Example 132
Preparation of Peptide Having SEQ ID NO:132
TABLE-US-00097 [0319] (SEQ ID NO: 132) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Ala Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn-NH2
[0320] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3157.6.
Example 133
Preparation of Peptide Having SEQ ID NO:133
TABLE-US-00098 [0321] (SEQ ID NO: 133) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Lys Ala Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn-NH2
[0322] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3100.5.
Example 134
Preparation of Peptide Having SEQ ID NO:134
TABLE-US-00099 [0323] (SEQ ID NO: 134) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Lys Ala Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn-NH2
[0324] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3100.5.
Example 135
Preparation of Peptide Having SEQ ID NO:135
TABLE-US-00100 [0325] (SEQ ID NO: 135) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Ala Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn-NH2
[0326] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3154.5.
Example 136
Preparation of Peptide Having SEQ ID NO:136
TABLE-US-00101 [0327] (SEQ ID NO: 136) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Ala Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn-NH2
[0328] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3115.5.
Example 137
Preparation of Peptide Having SEQ ID NO:137
TABLE-US-00102 [0329] (SEQ ID NO: 137) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Pentylgly Glu Glu Glu Ala Val Arg Leu Phe
Ile Glu Trp Leu Lys Asn-NH2
[0330] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3212.4.
Example 138
Preparation of Peptide Having SEQ ID NO:138
TABLE-US-00103 [0331] (SEQ ID NO: 138) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Pentylgly Glu Glu Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn-NH2
[0332] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3173.4.
Example 139
Preparation of Peptide Having SEQ ID NO:139
TABLE-US-00104 [0333] (SEQ ID NO: 139) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Ala Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn-NH2
[0334] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3156.6.
Example 140
Preparation of Peptide Having SEQ ID NO:140
TABLE-US-00105 [0335] (SEQ ID NO: 140) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Ala Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn-NH2
[0336] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3099.5.
Example 141
Preparation of Peptide Having SEQ ID NO:141
TABLE-US-00106 [0337] (SEQ ID NO: 141) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Ala Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn-NH2
[0338] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3156.6.
Example 142
Preparation of Peptide Having SEQ ID NO:142
TABLE-US-00107 [0339] (SEQ ID NO: 142) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Ala Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn-NH2
[0340] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3099.5.
Example 143
Preparation of Peptide Having SEQ ID NO:143
TABLE-US-00108 [0341] (SEQ ID NO: 143) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Ala Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn-NH2
[0342] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3156.6.
Example 144
Preparation of Peptide Having SEQ ID NO:144
TABLE-US-00109 [0343] (SEQ ID NO: 144) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Ala Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn-NH2
[0344] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3099.5.
Example 145
Preparation of Peptide Having SEQ ID NO:145
TABLE-US-00110 [0345] (SEQ ID NO: 145) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Ala Arg Leu Phe Ile Glu
Trp Leu Lys Asn-NH2
[0346] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3186.6.
Example 146
Preparation of Peptide Having SEQ ID NO:146
TABLE-US-00111 [0347] (SEQ ID NO: 146) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Ala Arg Leu Phe Ile Glu
Phe Leu Lys Asn-NH2
[0348] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3129.5.
Example 147
Preparation of Peptide Having SEQ ID NO:147
TABLE-US-00112 [0349] (SEQ ID NO: 147) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Ala Leu Phe Ile Glu
Trp Leu Lys Asn-NH2
[0350] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3129.5.
Example 148
Preparation of Peptide Having SEQ ID NO:148
TABLE-US-00113 [0351] (SEQ ID NO: 148) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Ala Leu Phe Ile Glu
Phe Leu Lys Asn-NH2
[0352] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3072.4.
Example 149
Preparation of Peptide Having SEQ ID NO:149
TABLE-US-00114 [0353] (SEQ ID NO: 149) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Ala Phe Ile Glu
Trp Leu Lys Asn-NH2
[0354] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3172.5.
Example 150
Preparation of Peptide Having SEQ ID NO:150
TABLE-US-00115 [0355] (SEQ ID NO: 150) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Ala Phe Ile Glu
Phe Leu Lys Asn-NH2
[0356] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3115.5.
Example 151
Preparation of Peptide Having SEQ ID NO:151
TABLE-US-00116 [0357] (SEQ ID NO: 151) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Naphthylala
Ile Glu Trp Leu Lys Asn-NH2
[0358] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3266.4.
Example 152
Preparation of Peptide Having SEQ ID NO:152
TABLE-US-00117 [0359] (SEQ ID NO: 152) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Naphthylala
Ile Glu Phe Leu Lys Asn-NH2
[0360] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3209.4.
Example 153
Preparation of Peptide Having SEQ ID NO:153
TABLE-US-00118 [0361] (SEQ ID NO: 153) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Val Glu
Trp Leu Lys Asn-NH2
[0362] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3200.6.
Example 154
Preparation of Peptide Having SEQ ID NO:154
TABLE-US-00119 [0363] (SEQ ID NO: 154) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Val Glu
Phe Leu Lys Asn-NH2
[0364] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3143.5.
Example 155
Preparation of Peptide Having SEQ ID NO:155
TABLE-US-00120 [0365] (SEQ ID NO: 155) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe
tButylgly Glu Trp Leu Lys Asn-NH2
[0366] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3216.5.
Example 156
Preparation of Peptide Having SEQ ID NO:156
TABLE-US-00121 [0367] (SEQ ID NO: 156) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe
tButylgly Glu Phe Leu Lys Asn-NH2
[0368] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3159.4.
Example 157
Preparation of Peptide Having SEQ ID NO:157
TABLE-US-00122 [0369] (SEQ ID NO: 157) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Asp
Trp Leu Lys Asn-NH2
[0370] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3200.6.
Example 158
Preparation of Peptide Having SEQ ID NO:158
TABLE-US-00123 [0371] (SEQ ID NO: 158) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Asp
Phe Leu Lys Asn-NH2
[0372] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3143.5.
Example 159
Preparation of Peptide Having SEQ ID NO:159
TABLE-US-00124 [0373] (SEQ ID NO: 159) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Ala Leu Lys Asn-NH2
[0374] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3099.5.
Example 160
Preparation of Peptide Having SEQ ID NO:160
TABLE-US-00125 [0375] (SEQ ID NO: 160) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Ala Leu Lys Asn-NH2
[0376] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3081.4.
Example 161
Preparation of Peptide Having SEQ ID NO:161
TABLE-US-00126 [0377] (SEQ ID NO: 161) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Ala Lys Asn-NH2
[0378] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3172.5.
Example 162
Preparation of Peptide Having SEQ ID NO:162
TABLE-US-00127 [0379] (SEQ ID NO: 162) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Ala Lys Asn-NH2
[0380] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3115.5.
Example 163
Preparation of Peptide Having SEQ ID NO:163
TABLE-US-00128 [0381] (SEQ ID NO: 163) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Ala Asn-NH2
[0382] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3157.5.
Example 164
Preparation of Peptide Having SEQ ID NO:164
TABLE-US-00129 [0383] (SEQ ID NO: 164) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Ala Asn-NH2
[0384] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3100.4.
Example 165
Preparation of Peptide Having SEQ ID NO:165
TABLE-US-00130 [0385] (SEQ ID NO: 165) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Ala-NH2
[0386] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3171.6.
Example 166
Preparation of Peptide Having SEQ ID NO:166
TABLE-US-00131 [0387] (SEQ ID NO: 166) Ala Gly Asp Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Ala-NH2
[0388] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3114.5.
Example 167
Preparation of Peptide Having SEQ ID NO:167
TABLE-US-00132 [0389] (SEQ ID NO: 167) Ala Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro-NH2
[0390] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 4033.5.
Example 168
Preparation of Peptide Having SEQ ID NO:168
TABLE-US-00133 [0391] (SEQ ID NO: 168) His Gly Ala Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro-NH2
[0392] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3984.4.
Example 169
Preparation of Peptide Having SEQ ID NO:169
TABLE-US-00134 [0393] (SEQ ID NO: 169) His Gly Glu Ala Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro-NH2
[0394] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 4016.5.
Example 170
Preparation of Peptide Having SEQ ID NO:170
TABLE-US-00135 [0395] (SEQ ID NO: 170) His Gly Glu Gly Thr Phe Thr
Ser Ala Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro-NH2
[0396] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3861.3.
Example 171
Preparation of Peptide Having SEQ ID NO:171
TABLE-US-00136 [0397] (SEQ ID NO: 171) Ala Gly Glu Gly Thr Phe Thr
Ser Asp Ala Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro-NH2
[0398] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3746.1.
Example 172
Preparation of Peptide Having SEQ ID NO:172
TABLE-US-00137 [0399] (SEQ ID NO: 172 Ala Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala-NH2
[0400] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3742.1.
Example 173
Preparation of Peptide Having SEQ ID NO:173
TABLE-US-00138 [0401] (SEQ ID NO: 173) His Gly Ala Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala-NH2
[0402] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3693.1.
Example 174
Preparation of Peptide Having SEQ ID NO:174
TABLE-US-00139 [0403] (SEQ ID NO: 174) His Gly Glu Ala Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly-NH2
[0404] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3751.2.
Example 175
Preparation of Peptide Having SEQ ID NO:175
TABLE-US-00140 [0405] (SEQ ID NO: 175) His Gly Glu Gly Thr Phe Thr
Ser Ala Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn Gly Gly Pro Ser Ser-NH2
[0406] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3634.1.
Example 176
Preparation of Peptide Having SEQ ID NO:176
TABLE-US-00141 [0407] (SEQ ID NO: 176) Ala Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn Gly Gly Pro Ser-NH2
[0408] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3526.9.
Example 177
Preparation of Peptide Having SEQ ID NO:177
TABLE-US-00142 [0409] (SEQ ID NO: 177) His Gly Ala Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn Gly Gly Pro Ser-NH2
[0410] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3477.9.
Example 178
Preparation of Peptide Having SEQ ID NO:178
TABLE-US-00143 [0411] (SEQ ID NO: 178) His Gly Glu Ala Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn Gly Gly Pro-NH2
[0412] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3519.9.
Example 179
Preparation of Peptide Having SEQ ID NO:179
TABLE-US-00144 [0413] (SEQ ID NO: 179) His Gly Glu Gly Thr Phe Thr
Ser Ala Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn Gly Gly-NH2
[0414] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3307.7.
Example 180
Preparation of Peptide Having SEQ ID NO:180
TABLE-US-00145 [0415] (SEQ ID NO: 180) Ala Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn Gly-NH2
[0416] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3186.5.
Example 181
Preparation of Peptide Having SEQ ID NO:181
TABLE-US-00146 [0417] (SEQ ID NO: 181) His Gly Ala Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn Gly Gly tPro Ser Ser Gly Ala tPro tPro tPro-NH2
[0418] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Double couplings are required at residues 37, 36 and 31. Used
in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1%
TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 4121.1.
Example 182
Preparation of Peptide Having SEQ ID NO:182
TABLE-US-00147 [0419] (SEQ ID NO: 182) His Gly Glu Ala Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala tPro tPro tPro-NH2
[0420] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Double couplings are required at residues 37, 36 and 31. Used
in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1%
TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 4173.2.
Example 183
Preparation of Peptide Having SEQ ID NO:183
TABLE-US-00148 [0421] (SEQ ID NO: 183) His Gly Glu Gly Thr Phe Thr
Ser Ala Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn Gly Gly NMeala Ser Ser Gly Ala NMeala
NMeala-NH2
[0422] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Compound 1.
Double couplings are required at residues 36 and 31. Used in
analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry (M): calculated 3796.1.
Example 184
Preparation of Peptide Having SEQ ID NO:184
TABLE-US-00149 [0423] (SEQ ID NO: 184) Ala Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn Gly Gly hPro Ser Ser Gly Ala hPro-NH2
[0424] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. A double coupling is required at residue 31. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over
30 minutes) of the lyophilized peptide is then carried out to
determine the retention time of the product peptide. Electrospray
Mass Spectrometry (M): calculated 3871.1.
Example 185
Preparation of Peptide Having SEQ ID NO:185
TABLE-US-00150 [0425] (SEQ ID NO: 185) His Gly Ala Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala-NH2
[0426] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3750.2.
Example 186
Preparation of Peptide Having SEQ ID NO:186
TABLE-US-00151 [0427] (SEQ ID NO: 186) His Gly Asp Ala Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn Gly Gly-NH2
[0428] The above-identified amdiated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 3408.8.
Example 187
Preparation of Peptide Having SEQ ID NO:187
TABLE-US-00152 [0429] (SEQ ID NO: 187) Ala Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser-NH2
[0430] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 4120.6.
Example 188
Preparation of Peptide Having SEQ ID NO:188
TABLE-US-00153 [0431] (SEQ ID NO: 188) Ala Gly Ala Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu
Phe Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser-NH2
[0432] The above-identified amidated peptide is assembled on
4-(2'-4'-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide
norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using
Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from
the resin, deprotected and purified in a similar way to Example
100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent
B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%
Solvent B in Solvent A over 30 minutes) of the lyophilized peptide
is then carried out to determine the retention time of the product
peptide. Electrospray Mass Spectrometry (M): calculated 4005.5.
Example 189
Preparation of C-Terminal Carboxylic Acid Peptides Corresponding to
the Above C-Terminal Amide Sequences for Peptides Having SEQ ID
NOs:100-166, 172-177, 179-180 and 185-188
[0433] C-terminal carboxylic acid peptides corresponding to
amidated having SEQ ID NOs:100-166, 172-177, 179-180 and 185-188
are assembled on the so called Wang resin (p-alkoxybenzylalacohol
resin (Bachem, 0.54 mmole/g)) using Fmoc-protected amino acids
(Applied Biosystems, Inc.), cleaved from the resin, deprotected and
purified in a similar way to that described in Example 100. Used in
analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA
in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in
Solvent A over 30 minutes) of the lyophilized peptide is then
carried out to determine the retention time of the product peptide.
Electrospray Mass Spectrometry provides an experimentally
determined (M).
Example 190
Preparation of C-Terminal Carboxylic Acid Peptides Corresponding to
the Above C-Terminal Amide Sequences for Peptides Having SEQ ID
NOs:167-171, 178 and 181-184
[0434] C-terminal carboxylic acid eptides corresponding to amidated
SEQ ID NOs:167-171, 178 and 181-184 are assembled on the
2-chlorotritylchloride resin (200-400 mesh), 2% DVB (Novabiochem,
0.4-1.0 mmole/g)) using Fmoc-protected amino acids (Applied
Biosystems, Inc.), cleaved from the resin, deprotected and purified
in a similar way to that described in Example 100. Used in analysis
are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).
Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over
30 minutes) of the lyophilized peptide is then carried out to
determine the retention time of the product peptide. Electrospray
Mass Spectrometry provides an experimentally determined (M).
[0435] Various modifications of the invention in addition to those
shown and described herein will become apparent to those skilled in
the art from the foregoing description and fall within the scope of
the following claims.
Sequence CWU 1
1
188139PRTHeloderma horridumAMIDATION(39)...(39)amidated Ser
(Serinamide) 1His Ser Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln
Met Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys
Asn Gly Gly Pro Ser 20 25 30Ser Gly Ala Pro Pro Pro Ser
35239PRTHeloderma suspectumAMIDATION(39)...(39)amidated Ser
(Serinamide) 2His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln
Met Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys
Asn Gly Gly Pro Ser 20 25 30Ser Gly Ala Pro Pro Pro Ser
35339PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 3Xaa Xaa Xaa Gly Thr Xaa Xaa Xaa Xaa
Xaa Ser Lys Gln Xaa Glu Glu 1 5 10 15Glu Ala Val Arg Leu Xaa Xaa
Xaa Xaa Leu Lys Asn Gly Gly Xaa Ser 20 25 30Ser Gly Ala Xaa Xaa Xaa
Xaa 35438PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 4Xaa Xaa Xaa Gly Xaa Xaa Xaa Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15Xaa Ala Xaa Xaa Xaa Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30Xaa Xaa Xaa Xaa Xaa Xaa
35539PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 5Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15Xaa Ala Xaa Xaa Xaa Xaa Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30Xaa Xaa Xaa Xaa Xaa Xaa
Xaa 35630PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 6His Gly Glu Gly Thr Phe Thr Ser Asp
Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile
Glu Trp Leu Lys Asn Gly Gly 20 25 30730PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 7His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly 20 25 30828PRTArtificial Sequenceartificially synthesized
sequence of novel exendin agonist compound 8His Gly Glu Gly Thr Phe
Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg
Leu Ala Ile Glu Phe Leu Lys Asn 20 25939PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 9His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn
Gly Gly Pro Ser 20 25 30Ser Gly Ala Pro Pro Pro Ser
351039PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 10His Gly Glu Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30Ser Gly Ala Pro Pro
Pro Ser 351139PRTArtificial Sequenceartificially synthesized
sequence of novel exendin agonist compound 11His Gly Glu Gly Thr
Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val
Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly Pro Ser 20 25 30Ser Gly
Ala Pro Pro Pro Ser 351239PRTArtificial Sequenceartificially
synthesized sequence of novel exendin agonist compound 12Tyr Gly
Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 1 5 10
15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser
20 25 30Ser Gly Ala Pro Pro Pro Ser 351339PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 13His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly Pro Ser 20 25 30Ser Gly Ala Pro Pro Pro Tyr
351439PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 14His Gly Asp Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30Ser Gly Ala Pro Pro
Pro Ser 351539PRTArtificial Sequenceartificially synthesized
sequence of novel exendin agonist compound 15His Gly Glu Gly Thr
Xaa Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val
Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30Ser Gly
Ala Pro Pro Pro Ser 351639PRTArtificial Sequenceartificially
synthesized sequence of novel exendin agonist compound 16His Gly
Glu Gly Thr Phe Ser Ser Asp Leu Ser Lys Gln Met Glu Glu 1 5 10
15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser
20 25 30Ser Gly Ala Pro Pro Pro Ser 351739PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 17His Gly Glu Gly Thr Phe Ser Thr Asp Leu Ser Lys Gln Met
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly Pro Ser 20 25 30Ser Gly Ala Pro Pro Pro Ser
351839PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 18His Gly Glu Gly Thr Phe Thr Thr
Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30Ser Gly Ala Pro Pro
Pro Ser 351939PRTArtificial Sequenceartificially synthesized
sequence of novel exendin agonist compound 19His Gly Glu Gly Thr
Phe Thr Ser Glu Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val
Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30Ser Gly
Ala Pro Pro Pro Ser 352039PRTArtificial Sequenceartificially
synthesized sequence of novel exendin agonist compound 20His Gly
Glu Gly Thr Phe Thr Ser Asp Xaa Ser Lys Gln Met Glu Glu 1 5 10
15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser
20 25 30Ser Gly Ala Pro Pro Pro Ser 352139PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 21His Gly Glu Gly Thr Phe Thr Ser Asp Xaa Ser Lys Gln Leu
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn
Gly Gly Pro Ser 20 25 30Ser Gly Ala Pro Pro Pro Ser
352239PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 22His Gly Glu Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Xaa Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30Ser Gly Ala Pro Pro
Pro Ser 352339PRTArtificial Sequenceartificially synthesized
sequence of novel exendin agonist compound 23His Gly Glu Gly Thr
Phe Thr Ser Asp Leu Ser Lys Gln Xaa Glu Glu 1 5 10 15Glu Ala Val
Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly Pro Ser 20 25 30Ser Gly
Ala Pro Pro Pro Ser 352439PRTArtificial Sequenceartificially
synthesized sequence of novel exendin agonist compound 24His Gly
Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 1 5 10
15Glu Ala Val Arg Leu Xaa Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser
20 25 30Ser Gly Ala Pro Pro Pro Ser 352539PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 25His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Val Glu Trp Leu Lys Asn
Gly Gly Pro Ser 20 25 30Ser Gly Ala Pro Pro Pro Ser
352639PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 26His Gly Glu Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Val Glu Phe Leu Lys Asn Gly Gly Pro Ser 20 25 30Ser Gly Ala Pro Pro
Pro Ser 352739PRTArtificial Sequenceartificially synthesized
sequence of novel exendin agonist compound 27His Gly Glu Gly Thr
Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val
Arg Leu Phe Xaa Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30Ser Gly
Ala Pro Pro Pro Ser 352839PRTArtificial Sequenceartificially
synthesized sequence of novel exendin agonist compound 28His Gly
Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10
15Glu Ala Val Arg Leu Phe Xaa Glu Phe Leu Lys Asn Gly Gly Pro Ser
20 25 30Ser Gly Ala Pro Pro Pro Ser 352939PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 29His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Asp Trp Leu Lys Asn
Gly Gly Pro Ser 20 25 30Ser Gly Ala Pro Pro Pro Ser
353039PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 30His Gly Glu Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn Gly Gly Pro Ser 20 25 30Ser Gly Ala Pro Pro
Pro Ser 353139PRTArtificial Sequenceartificially synthesized
sequence of novel exendin agonist compound 31His Gly Glu Gly Thr
Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val
Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Xaa Ser 20 25 30Ser Gly
Ala Xaa Xaa Xaa Ser 353239PRTArtificial Sequenceartificially
synthesized sequence of novel exendin agonist compound 32His Gly
Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 1 5 10
15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser
20 25 30Ser Gly Ala Xaa Xaa Xaa Ser 353339PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 33His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly Xaa Ser 20 25 30Ser Gly Ala Xaa Xaa Xaa Ser
353439PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 34His Gly Glu Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30Ser Gly Ala Xaa Xaa
Xaa Ser 353539PRTArtificial Sequenceartificially synthesized
sequence of novel exendin agonist compound 35His Gly Glu Gly Thr
Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val
Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly Xaa Ser 20 25 30Ser Gly
Ala Xaa Xaa Xaa Ser 353639PRTArtificial Sequenceartificially
synthesized sequence of novel exendin agonist compound 36His Gly
Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15
Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly Xaa Ser 20
25 30 Ser Gly Ala Xaa Xaa Xaa Ser 353739PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 37His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly Xaa Ser 20 25 30Ser Gly Ala Xaa Xaa Xaa Ser
353839PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 38His Gly Glu Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30Ser Gly Ala Xaa Xaa
Xaa Ser 353939PRTArtificial Sequenceartificially synthesized
sequence of novel exendin agonist compound 39His Gly Glu Gly Thr
Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val
Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly Xaa Ser 20 25 30Ser Gly
Ala Xaa Xaa Xaa Ser 354028PRTArtificial Sequenceartificially
synthesized sequence of novel exendin agonist compound 40His Gly
Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 1 5 10
15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn 20
254128PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 41His Gly Glu Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn 20 254228PRTArtificial Sequenceartificially
synthesized sequence of novel exendin agonist compound 42His Ala
Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10
15Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn 20
254328PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 43His Gly Glu Gly Ala Phe Thr Ser
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn 20 254428PRTArtificial Sequenceartificially
synthesized sequence of novel exendin agonist compound 44His Gly
Glu Gly Thr Ala Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10
15Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn 20
254528PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 45His Gly Glu Gly Thr Phe Thr Ala
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn 20 254628PRTArtificial Sequenceartificially
synthesized sequence of novel exendin agonist compound 46His Gly
Glu Gly Thr Phe Thr Ser Asp Ala Ser Lys Gln Leu Glu Glu 1 5 10
15Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn 20
254728PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 47His Gly Glu Gly Thr Phe Thr Ser
Asp Leu Ala Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn 20 254828PRTArtificial Sequenceartificially
synthesized sequence of novel exendin agonist compound 48His Gly
Glu Gly Thr Phe Thr Ser Asp Leu Ser Ala Gln Leu Glu Glu 1 5 10
15Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn 20
254928PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 49His Gly Glu Gly Thr Phe Thr Ser
Asp Leu Ser Lys Ala Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn 20 255028PRTArtificial Sequenceartificially
synthesized sequence of novel exendin agonist compound 50His Gly
Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Ala Glu Glu 1 5 10
15Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn 20
255128PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 51His Gly Glu Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Leu Ala Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn 20 255228PRTArtificial Sequenceartificially
synthesized
sequence of novel exendin agonist compound 52His Gly Glu Gly Thr
Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Ala 1 5 10 15Glu Ala Val
Arg Leu Phe Ile Glu Phe Leu Lys Asn 20 255328PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 53His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu 1 5 10 15Ala Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn 20
255428PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 54His Gly Glu Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Ala Arg Leu Phe
Ile Glu Phe Leu Lys Asn 20 255528PRTArtificial Sequenceartificially
synthesized sequence of novel exendin agonist compound 55His Gly
Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10
15Glu Ala Val Ala Leu Phe Ile Glu Phe Leu Lys Asn 20
255628PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 56His Gly Glu Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Ala Phe
Ile Glu Phe Leu Lys Asn 20 255728PRTArtificial Sequenceartificially
synthesized sequence of novel exendin agonist compound 57His Gly
Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10
15Glu Ala Val Arg Leu Phe Ile Ala Phe Leu Lys Asn 20
255828PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 58His Gly Glu Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Ala Leu Lys Asn 20 255928PRTArtificial Sequenceartificially
synthesized sequence of novel exendin agonist compound 59His Gly
Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10
15Glu Ala Val Arg Leu Phe Ile Glu Phe Ala Lys Asn 20
256028PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 60His Gly Glu Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Ala Asn 20 256128PRTArtificial Sequenceartificially
synthesized sequence of novel exendin agonist compound 61His Gly
Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10
15Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Ala 20
256238PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 62His Gly Glu Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30Ser Gly Ala Pro Pro
Pro 356338PRTArtificial Sequenceartificially synthesized sequence
of novel exendin agonist compound 63His Gly Glu Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn Gly Gly Pro Ser 20 25 30Ser Gly Ala Pro Pro
Pro 356437PRTArtificial Sequenceartificially synthesized sequence
of novel exendin agonist compound 64His Gly Glu Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30Ser Gly Ala Pro Pro
356537PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 65His Gly Glu Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn Gly Gly Pro Ser 20 25 30Ser Gly Ala Pro Pro
356636PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 66His Gly Glu Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30Ser Gly Ala Pro
356736PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 67His Gly Glu Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn Gly Gly Pro Ser 20 25 30Ser Gly Ala Pro
356835PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 68His Gly Glu Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30Ser Gly Ala
356935PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 69His Gly Glu Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn Gly Gly Pro Ser 20 25 30Ser Gly Ala
357034PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 70His Gly Glu Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30Ser
Gly7134PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 71His Gly Glu Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn Gly Gly Pro Ser 20 25 30Ser
Gly7233PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 72His Gly Glu Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25
30Ser7333PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 73His Gly Glu Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn Gly Gly Pro Ser 20 25
30Ser7432PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 74His Gly Glu Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 307532PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 75His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn
Gly Gly Pro Ser 20 25 307631PRTArtificial Sequenceartificially
synthesized sequence of novel exendin agonist compound 76His Gly
Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 1 5 10
15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro 20 25
307731PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 77His Gly Glu Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn Gly Gly Pro 20 25 307830PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 78His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn
Gly Gly 20 25 307929PRTArtificial Sequenceartificially synthesized
sequence of novel exendin agonist compound 79His Gly Glu Gly Thr
Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val
Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly 20 258029PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 80His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn
Gly 20 258138PRTArtificial Sequenceartificially synthesized
sequence of novel exendin agonist compound 81His Gly Glu Gly Thr
Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val
Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Xaa Ser 20 25 30Ser Gly
Ala Xaa Xaa Xaa 358238PRTArtificial Sequenceartificially
synthesized sequence of novel exendin agonist compound 82His Gly
Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 1 5 10
15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser
20 25 30Ser Gly Ala Xaa Xaa Xaa 358337PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 83His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly Xaa Ser 20 25 30Ser Gly Ala Pro Pro 358437PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 84His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly Xaa Ser 20 25 30Ser Gly Ala Xaa Xaa 358537PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 85His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly Xaa Ser 20 25 30Ser Gly Ala Xaa Xaa 358636PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 86His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly Xaa Ser 20 25 30Ser Gly Ala Xaa 358735PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 87Arg Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly Pro Ser 20 25 30Ser Gly Ala 358830PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 88His Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly 20 25 308928PRTArtificial Sequenceartificially synthesized
sequence of novel exendin agonist compound 89His Gly Glu Gly Thr
Xaa Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val
Arg Leu Phe Ile Glu Phe Leu Lys Asn 20 259028PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 90His Gly Glu Gly Thr Phe Ser Ser Asp Leu Ser Lys Gln Met
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn 20
259128PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 91His Gly Glu Gly Thr Phe Ser Thr
Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Trp Leu Lys Asn 20 259228PRTArtificial Sequenceartificially
synthesized sequence of novel exendin agonist compound 92His Gly
Glu Gly Thr Phe Thr Ser Glu Leu Ser Lys Gln Met Ala Glu 1 5 10
15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn 20
259328PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 93His Gly Glu Gly Thr Phe Thr Ser
Asp Xaa Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn 20 259428PRTArtificial Sequenceartificially
synthesized sequence of novel exendin agonist compound 94His Gly
Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10
15Glu Ala Val Arg Leu Xaa Ile Glu Phe Leu Lys Asn 20
259528PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 95His Gly Glu Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Xaa Glu Trp Leu Lys Asn 20 259628PRTArtificial Sequenceartificially
synthesized sequence of novel exendin agonist compound 96His Gly
Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10
15Glu Ala Val Arg Leu Phe Ile Asp Phe Leu Lys Asn 20
259733PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 97His Gly Glu Gly Thr Phe Thr Ser
Asp Ala Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn Gly Gly Pro Ser 20 25
30Ser9829PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 98His Gly Glu Gly Thr Phe Thr Ser
Asp Ala Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Trp Leu Lys Asn Gly 20 259937PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 99His Gly Glu Gly Thr Phe Thr Ser Asp Ala Ser Lys Gln Met
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly Xaa Ser 20 25 30Ser Gly Ala Xaa Xaa 3510028PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 100Ala Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn 20
2510128PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 101His Gly Ala Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn 20 2510228PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 102His Gly Glu Ala Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn 20
2510328PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 103His Gly Glu Gly Thr Phe Thr Ser
Ala Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn 20 2510428PRTArtificial
SequenceAMIDATION(28)...(28)amidated Asn (Asparaginamide) 104Ala
Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 1 5 10
15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn 20
2510528PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 105His Gly Ala Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Trp Leu Lys Asn 20 2510628PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 106His Gly Glu Ala Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
20
2510728PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 107His Gly Glu Gly Thr Phe Thr Ser
Ala Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Trp Leu Lys Asn 20 2510828PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 108His Gly Glu Gly Thr Phe Thr Ser Asp Ala Ser Lys Gln Met
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn 20
2510928PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 109Ala Ala Glu Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Trp Leu Lys Asn 20 2511028PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 110Ala Ala Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn 20
2511128PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 111Ala Gly Asp Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Trp Leu Lys Asn 20 2511228PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 112Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn 20
2511328PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 113Ala Gly Asp Gly Ala Phe Thr Ser
Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Trp Leu Lys Asn 20 2511428PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 114Ala Gly Asp Gly Ala Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn 20
2511528PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 115Ala Gly Asp Gly Thr Xaa Thr Ser
Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Trp Leu Lys Asn 20 2511628PRTArtificial SequenceXaa in
position 6 stands for naphthylalanine. 116Ala Gly Asp Gly Thr Xaa
Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg
Leu Phe Ile Glu Phe Leu Lys Asn 20 2511728PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 117Ala Gly Asp Gly Thr Phe Ser Ser Asp Leu Ser Lys Gln Met
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn 20
2511828PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 118Ala Gly Asp Gly Thr Phe Ser Ser
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn 20 2511928PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 119Ala Gly Asp Gly Thr Phe Thr Ala Asp Leu Ser Lys Gln Met
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn 20
2512028PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 120Ala Gly Asp Gly Thr Phe Thr Ala
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn 20 2512128PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 121Ala Gly Asp Gly Thr Phe Thr Ser Ala Leu Ser Lys Gln Met
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn 20
2512228PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 122Ala Gly Asp Gly Thr Phe Thr Ser
Ala Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn 20 2512328PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 123Ala Gly Asp Gly Thr Phe Thr Ser Glu Leu Ser Lys Gln Met
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn 20
2512428PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 124Ala Gly Asp Gly Thr Phe Thr Ser
Glu Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn 20 2512528PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 125Ala Gly Asp Gly Thr Phe Thr Ser Asp Ala Ser Lys Gln Met
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn 20
2512628PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 126Ala Gly Asp Gly Thr Phe Thr Ser
Asp Ala Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn 20 2512728PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 127Ala Gly Asp Gly Thr Phe Thr Ser Asp Xaa Ser Lys Gln Met
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn 20
2512828PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 128Ala Gly Asp Gly Thr Phe Thr Ser
Asp Xaa Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn 20 2512928PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 129Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ala Lys Gln Met
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn 20
2513028PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 130Ala Gly Asp Gly Thr Phe Thr Ser
Asp Leu Ala Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn 20 2513128PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 131Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Ala Gln Met
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn 20
2513228PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 132Ala Gly Asp Gly Thr Phe Thr Ser
Asp Leu Ser Ala Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn 20 2513328PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 133Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Ala Met
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn 20
2513428PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 134Ala Gly Asp Gly Thr Phe Thr Ser
Asp Leu Ser Lys Ala Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn 20 2513528PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 135Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Ala
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn 20
2513628PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 136Ala Gly Asp Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Ala Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn 20 2513728PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 137Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Xaa
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn 20
2513828PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 138Ala Gly Asp Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Xaa Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn 20 2513928PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 139Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Ala Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn 20
2514028PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 140Ala Gly Asp Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Leu Ala Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn 20 2514128PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 141Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Ala 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn 20
2514228PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 142Ala Gly Asp Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Leu Glu Ala 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn 20 2514328PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 143Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu 1 5 10 15Ala Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn 20
2514428PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 144Ala Gly Asp Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Ala Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn 20 2514528PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 145Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu 1 5 10 15Glu Ala Ala Arg Leu Phe Ile Glu Trp Leu Lys Asn 20
2514628PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 146Ala Gly Asp Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Ala Arg Leu Phe
Ile Glu Phe Leu Lys Asn 20 2514728PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 147Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu 1 5 10 15Glu Ala Val Ala Leu Phe Ile Glu Trp Leu Lys Asn 20
2514828PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 148Ala Gly Asp Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Ala Leu Phe
Ile Glu Phe Leu Lys Asn 20 2514928PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 149Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu 1 5 10 15Glu Ala Val Arg Ala Phe Ile Glu Trp Leu Lys Asn 20
2515028PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 150Ala Gly Asp Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Ala Phe
Ile Glu Phe Leu Lys Asn 20 2515128PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 151Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Xaa Ile Glu Trp Leu Lys Asn 20
2515228PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 152Ala Gly Asp Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Xaa
Ile Glu Phe Leu Lys Asn 20 2515328PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 153Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Val Glu Trp Leu Lys Asn 20
2515428PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 154Ala Gly Asp Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Val Glu Phe Leu Lys Asn 20 2515528PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 155Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Xaa Glu Trp Leu Lys Asn 20
2515628PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 156Ala Gly Asp Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Xaa Glu Phe Leu Lys Asn 20 2515728PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 157Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Asp Trp Leu Lys Asn 20
2515828PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 158Ala Gly Asp Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Asp Phe Leu Lys Asn 20 2515928PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 159Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Ala Leu Lys Asn 20
2516028PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 160Ala Gly Asp Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Ala Leu Lys Asn 20 2516128PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 161Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Trp Ala Lys Asn 20
2516228PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 162Ala Gly Asp Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Phe Ala Lys Asn 20 2516328PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 163Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Ala Asn 20
2516428PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 164Ala Gly Asp Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Ala Asn 20
2516528PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 165Ala Gly Asp Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Trp Leu Lys Ala 20 2516628PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 166Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Ala 20
2516738PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 167Ala Gly Glu Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30Ser Gly Ala Pro Pro
Pro 3516838PRTArtificial Sequenceartificially synthesized sequence
of novel exendin agonist compound 168His Gly Ala Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu
Phe Ile Glu Phe Leu Lys Asn Gly Gly Pro Ser 20 25 30Ser Gly Ala Pro
Pro Pro 3516937PRTArtificial Sequenceartificially synthesized
sequence of novel exendin agonist compound 169His Gly Glu Ala Thr
Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val
Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30Ser Gly
Ala Pro Pro 3517036PRTArtificial Sequenceartificially synthesized
sequence of novel exendin agonist compound 170His Gly Glu Gly Thr
Phe Thr Ser Ala Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val
Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30Ser Gly
Ala Pro 3517136PRTArtificial Sequenceartificially synthesized
sequence of novel exendin agonist compound 171Ala Gly Glu Gly Thr
Phe Thr Ser Asp Ala Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val
Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly Pro Ser 20 25 30Ser Gly
Ala Pro 3517235PRTArtificial Sequenceartificially synthesized
sequence of novel exendin agonist compound 172Ala Gly Glu Gly Thr
Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val
Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30Ser Gly
Ala 3517335PRTArtificial Sequenceartificially synthesized sequence
of novel exendin agonist compound 173His Gly Ala Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu
Phe Ile Glu Phe Leu Lys Asn Gly Gly Pro Ser 20 25 30Ser Gly Ala
3517434PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 174His Gly Glu Ala Thr Phe Thr Ser
Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30Ser
Gly17533PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 175His Gly Glu Gly Thr Phe Thr Ser
Ala Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25
30Ser17632PRTArtificial Sequenceartificially synthesized sequence
of novel exendin agonist compound 176Ala Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val Arg Leu
Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25
3017732PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 177His Gly Ala Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn Gly Gly Pro Ser 20 25 3017831PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 178His Gly Glu Ala Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly Pro 20 25 3017930PRTArtificial Sequenceartificially
synthesized sequence of novel exendin agonist compound 179His Gly
Glu Gly Thr Phe Thr Ser Ala Leu Ser Lys Gln Leu Glu Glu 1 5 10
15Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly 20 25
3018029PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 180Ala Gly Glu Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn Gly 20 2518138PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 181His Gly Ala Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly Xaa Ser 20 25 30Ser Gly Ala Xaa Xaa Xaa
3518238PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 182His Gly Glu Ala Thr Phe Thr Ser
Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30Ser Gly Ala Xaa Xaa
Xaa 3518337PRTArtificial Sequenceartificially synthesized sequence
of novel exendin agonist compound 183His Gly Glu Gly Thr Phe Thr
Ser Ala Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val Arg Leu
Phe Ile Glu Trp Leu Lys Asn Gly Gly Xaa Ser 20 25 30Ser Gly Ala Xaa
Xaa 3518436PRTArtificial Sequenceartificially synthesized sequence
of novel exendin agonist compound 184Ala Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val Arg Leu
Phe Ile Glu Trp Leu Lys Asn Gly Gly Xaa Ser 20 25 30Ser Gly Ala Xaa
3518535PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 185His Gly Ala Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30Ser Gly Ala
3518630PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 186His Gly Asp Ala Thr Phe Thr Ser
Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Trp Leu Lys Asn Gly Gly 20 25 3018739PRTArtificial
Sequenceartificially synthesized sequence of novel exendin agonist
compound 187Ala Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Gly Gly Pro Ser 20 25 30Ser Gly Ala Pro Pro Pro Ser
3518839PRTArtificial Sequenceartificially synthesized sequence of
novel exendin agonist compound 188Ala Gly Ala Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn Gly Gly Pro Ser 20 25 30Ser Gly Ala Pro Pro
Pro Ser 35
* * * * *